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Background: Preterm birth accounts for ~10% of all births and is now an established risk factor for the 
development of metabolic syndrome, a cluster of conditions responsible for significant morbidity and 
mortality in New Zealand. The mechanisms underlying the development of Non alcoholic fatty liver disease 
(NAFLD, the hepatic manifestation of metabolic syndrome) in the ex-preterm are unknown at present. This 
project investigated potential differences between term and preterm born guinea pigs in the biological 
pathways believed to be associated with non-alcoholic fatty liver disease, including metabolism, and 
molecular and physiologic changes within the liver.  
Methods: Guinea pigs were delivered spontaneously at term (~GA69days), or prematurely by 
pharmacological induction of labour (GA62; equivalent to 32 weeks in humans). Fasting blood sugar levels 
(BSL) were taken at birth, and weekly thereafter. At corrected postnatal age (CPNA) 28 days (equivalent to 
early childhood in humans), glucose tolerance tests were performed, followed by euthanasia and collection 
of tissues. The prevalence of NALFD at CPNA 28 days was investigated using a NAFLD activity score based 
on histological methods and stains to visualise steatosis (oil red o), fibrosis (Masson’s trichome) and 
inflammation (H&E) in the liver. To observe hepatic alterations at a molecular level, amino acid profiles 
were assessed by liquid chromotography-tandem mass spectroscopy (LC-MS/MS). 
Results: Lower BSL at birth was observed in preterms compared to terms (p=0.001), however, BSL was 
higher in preterms than term counterparts at TEA (p<0.001). Preterms had a significant increase in hepatic 
steatosis at CPNA 28 days (p=0.0428) Inflammation was not significantly increased in preterms (p=0.4823), 
and pathologic fibrosis was not observed in any individuals enrolled in the study. Decreased concentrations 
of essential amino acids associated with liver damage prevention were observed in preterms compared to 
terms, including tryptophan (p=0.0242) and leucine (p=0.0174). Preterm cohorts had increased 
concentrations of cysteine (p<0.001) an amino acid associated with hepatic steatosis. 
Conclusions: Prematurity results in significant changes to hepatic metabolic function in the neonate. This 
deficit is reduced upon reaching term equivalent age, however molecular and physiological changes within 
the liver persisted into early childhood. In identifying metabolic, molecular and physiological alterations in 
the preterm guinea pig this study has begun to elucidate the pathways involved in preterm susceptibility 
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ANOVA Analysis of Variance 
AUC Area under curve 
BMI Body mass index 
Boar Adult male guinea pig 
BRU Biomedical research unit 
BSL Blood sugar level 
CPAP Continuous positive airway pressure 
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1.1 Premature Birth 
 Premature birth in New Zealand 
Preterm births account for 7.4% of New Zealand’s birth rate 1, with those born to Maori and low socio-
economic mothers being overrepresented 2,3. While the immediate effects detrimental to the premature 
neonate’s survival are widely recognized, there can be further complications that arise during the juvenile 
and adult stages of life that are less understood. Our understanding of the later-life effects, which stem 
from the developmental origin of preterm in utero growth have been shown to increase risk of 
cardiovascular disease, diabetes and components of metabolic syndrome in adults.  
 Later life complications of premature birth 
Due to advances made in neonatal care 45 years ago we are now seeing the first wave of moderately 
premature children enter middle age and along with them the first signs of serious complications as a result 
of their altered developmental environment. In 1972 Liggins & Howie 4 trialed the use of corticosteroids in 
human pregnancies where birth before 37 weeks was deemed likely. Antenatal betamethasone 
administered to accelerate lung maturation in the fetus was a significant improvement in neonatal care, 
significantly increasing the survival rate of premature babies below 32 weeks gestation. The trial would 
later become known as the ‘Auckland Steroid Study’. Thirty years later, Dalziel et al 5 investigated 
cardiovascular risk factors associated with preterm birth using the ‘Auckland Steroid Study’ cohort and 
demonstrated that gestational age was associated with increased systolic blood pressure and insulin 
resistance in adult life. This indicated that preterm birth has effects upon the individual that become 
apparent in later life. In Norway, Moster et al 6 used a similar cohort of premature babies to investigate the 
association of preterm birth with measures of wellbeing in adulthood. Medical and social criteria found to 
be associated with gestation age included mental retardation, education level, income, and receipt of 
disability or social security benefits. They concluded “medical and social disabilities in adulthood increase 
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with decreasing gestational age”. Studies such as these provide evidence of the long term challenge 
increased survival of premature babies confers; an expanding burden on national healthcare.  
 The effect of preterm later life complications on the health system 
As the survival of premature babies increases thanks to advancements in antenatal treatments and 
neonatal care, ex-preterms constitute an increasing proportion of the population 2. This is especially true 
for the Maori and low socioeconomic population as they are over represented in the premature birth rate 
3. An increased proportion of ex-preterm babies means an increased burden on the health system as they 
age and develop complications. It is therefore essential studies into the long term effects of preterm birth 
continue, so treatments and preventative strategies can be devised to prevent the manifestation of such 
effects. One such long term complication is the increased risk of metabolic syndrome 7. Comprised of 
multiple dysfunctions, metabolic syndrome and its components have long been shown to be associated 
with premature birth 5,8–11. 
1.2 Metabolic syndrome 
Metabolic syndrome (MetS) is an aggregation of conditions including abdominal obesity, insulin resistance, 
hypertension, and atherogenic dyslipidemia, which greatly increase the risk of developing cardiovascular 
disease (CVD) and type 2 Diabetes Mellitus (T2DM) 12.  Furthermore, not all conditions have to be present 
to be diagnosed with MetS. Currently, a diagnosis of MetS occurs if an individual exhibits 3 of the major 
metabolic dysfunctions 12. An individual with MetS is 2 times more likely to develop CVD within 5-10 years 
than an individual without, 5 times more likely to develop T2DM 12, 3 times more likely to suffer a stroke 
or develop coronary heart disease 13. As such, risk of mortality as a result of experiencing a cardiovascular 
event is increased 1.8 times 13. Risk of developing CVD or T2DM is increased with the number of MetS 
conditions the patient suffers. Increases seen in patients with 2 or more conditions are beyond what would 
be expected if the conditions were presented independently 13, indicating interaction between the 
conditions which exacerbate their effects. Furthermore, additional risk factors for CVD and T2DM 
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associated with MetS can include proinflammatory and prothrombotic states 14, hyperglycemia 15, Non-
alcoholic Fatty Liver Disease (NAFLD) 16, endothelial dysfunction 17, and chronic stress 18. 
Development of MetS is largely attributed to obesity 19, with insulin resistance stemming from adipocyte 
dysfunction acting as a major etiological factor 20,21. Due to MetS’s association with obesity and insulin 
resistance, rates of MetS and associated dysfunctions are increasing worldwide 22. MetS is predicted to 
continue increasing in prevalence ) and the hepatic manifestation of MetS, nonalcoholic fatty liver disease 
(NAFLD) 23 is expected to become the leading etiology for liver transplantation in the 21st century 24. Liver 
dysfunction may play a key role in the development of MetS due to the livers role in maintaining metabolic 
homeostasis 25. It has been proposed that NAFLD and MetS share common pathophysiological mechanisms 
16. Therefore the ability to determine a predisposition to NAFLD may provide an early indication of MetS 
susceptibility, opening the door for early intervention and treatment ahead of MetS manifestation.  
1.3 Nonalcoholic Fatty Liver Disease  
As the prevalence of MetS rapidly increases, so to has the occurrence of NAFLD. NAFLD’s close association 
with obesity results in rapidly increasing rate of the disease in developing and western countries where 
over nutrition and sedentary lifestyle 26–28 are increasingly the norm. Between 1988 and 2008 rates of 
NAFLD in the United States doubled, while other causes of liver disease remained stable 29. NAFLD 
manifests analogously to Alcoholic Fatty Liver Disease 30, in 1980 Ludwig et al 31 differentiated and entitled 
the disease through acknowledgement of its manifestation in the absence of excessive alcohol. As NAFLD 
can be asymptomatic 32, rates of diagnosis may be underestimated. When NAFLD is suspected, the gold 
standard for diagnosis requires liver biopsy, an invasive, risky and costly procedure 32; therefore biopsy is 
requested only when NAFLD is suspected and likely to result in complications. Non-invasive measures are 
limited in their sensitivity and staging abilities 33. A method of reliable non-invasive diagnosis is sought after 
as early detection prior to NAFLD development would be vastly beneficial in its allowance for intervention 
before disease development. 
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 NAFL v NASH development 
NAFLD is a spectrum disorder, comprised of two subtypes, nonalcoholic fatty liver (NAFL) - consisting of 
isolated steatosis, and nonalcoholic steatohepatitis (NASH) 34 - characterised by hepatocellular injury and 
inflammation which may or may not be accompanied by fibrosis. 30,35 NASH is considered to be the 
progressive form of NAFLD while NAFL until recently, was considered benign 36 with little risk of progression 
to cirrhosis, hepatocellular carcinoma (HCC), hepatic failure, or mortality 34. A follow-up study of patients 
histologically diagnosed with NAFLD 18 years prior concluded progression rates were not uniform across 
the NAFLD spectrum 34. All NAFLD cases (including NASH) had a 22% risk of progressing to unfavourable 
outcomes, while NAFL cases had only 4% risk. In line with this, meta-analysis of paired biopsies taken 1 year 
apart 37 revealed a subgroup within NAFL patients who had experienced rapid fibrosis progression. Further 
research is required to define the mechanisms surrounding this acceleration in fibrosis development, but 
Singh et al postulate the difference in progression maybe due to inflammation in these NAFL cases which 
had not resulted in steatohepatitis cellular characteristics. While isolated liver steatosis does not in itself 
confer an increased rate of mortality, the associated conditions, CVD and T2DM do. Further, an individual 
with NAFL has a 4% risk of progression to NASH and with that the risk of progression to HCC and cirrhosis. 
 Manifestation of NAFLD in the liver 
NAFLD incorporates 3 hepatic injuries, varying degrees of which confer NAFL or NASH (Figure 2, Figure 3, 
Figure 4) 
Steatosis - Lipid accumulation within the liver has been credited to an imbalance in four distinct 
mechanisms: excess triglycerides are stored within the hepatocytes when the rate of free fatty acid (FFA) 
uptake and de novo lipogenesis, exceed the rate of lipid oxidation, and VLDL secretion 38. Steatosis may be 
a protective adaptation to limit the lipotoxicity of excessive FFA and lipid metabolites on the liver 39. 
Steatosis can manifests as micro- and macro-vesicular lipid deposits, or hepatocyte hypertrophy and 
ballooning when accompanied by inflammation 40–42(Figure 3). 
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Inflammation - Inflammation of the hepatocytes as a result of systemic (originating from adipose tissue 
dysfunction) and local inflammation of the liver 43.  
Inflammation manifests as hepatocellular ballooning and white blood cell infiltration 44 and can result in 
cellular degeneration and apoptosis 45(Figure 4a). 
Fibrosis - Fibrosis is a potential outcome of hepatocyte degeneration and apoptosis. Inflamed cells release 
cytokines which stimulate fibrogenic cells to produce collagen 46.  Fibrosis manifests as an aggregation of 
extracellular collagen fibres occurring where damaged hepatocytes once existed. Fibrosis can impede liver 
































































































































































































































































































































































































































































































































































































Figure 2: H&E stained healthy liver tissue  
 
Figure 2: H&E stained healthy liver tissue – Liver tissue free from steatosis and inflammation 48.  
Figure 3: H&E stained manifestations of hepatocellular steatosis at various magnifications 
 
Figure 3: H&E stained manifestations of hepatocellular steatosis at various magnifications (A) Macrovesicular steatosis – singular 
large vacuoles displacing the hepatocyte nuclei. (B) Microvesicular steatosis – small vacuoles of lipid within the hepatocytes, arrow 
indicates a single hepatocyte with multiple lipid vacuoles. (C) Hepatocellular ballooning – enlargement of the hepatocyte 
(hypertrophy) with cytoplasmic degeneration indicated by arrow 49. 
 






Figure 4: Hepatic manifestation of fibrosis and inflammation. (A) Inflammation foci within liver hepatic tissue, white blood cell 
infiltration into the liver visible in dark purple 50. (B) Presinusoidal fibrosis of the liver, collagen fibres are visible in blue 51.   
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 The role of visceral adiposity and insulin resistance in NAFLD 
development 
 The impaired response to normal levels of insulin is key in the development of NAFLD 52: Insulin resistance 
associated with MetS and NAFLD is triggered by visceral obesity and the resulting dysfunction and 
inflammation of this adipose tissue 53. Oxygen supply to the increasing adipose tissue is limited due to 
hyperplasia and hypertrophy of the accumulating adipocytes, resulting in inflammation, apoptosis, and the 
release of FFA and adipokines (cytokines (cell signalling proteins) secreted by adipose tissue) 54. These 
adipokines act locally through autocrine and paracrine signalling on the adipose tissue itself 55, and 
systemically, through endocrine signalling of the skeletal muscle, liver, and pancreas to alter insulin 
sensitivity 56. Adipokines identified to play a key role in the manifestation of NAFLD and insulin resistance 
include;  
● TNF  - reduces insulin sensitivity by attenuation of ‘insulin receptor pathway 1’ in adipocytes 57.  
● IL-6 - chronically increased levels of IL-6 confer insulin resistance in liver tissue 58 via activation of 
inhibitory SOCS-3 proteins 59. 
● PIA-1 - associated with obesity and predictive of T2DM development, however suspected indirect 
effects on insulin sensitivity have not been fully elucidated 60,61.  
 
Lipolysis as a result of adipose dysfunction and insulin resistance increases circulation of FFA 62. Santomauro 
et al 63 demonstrated a temporary lowering of insulin resistance in both nondiabetic obese and diabetic 
obese patients when Acipimox was administered to reduce FFA levels, thus implicating FFAs as a causal 
element in insulin resistance. This is achieved via the inhibition of insulin dependent glucose uptake of 
skeletal muscles, and increasing gluconeogenesis in the liver 64. Acute levels of FFA induce insulin secretion, 
while longer periods of FFA elevation impair insulin production 65. A positive feedback loop is created 
between insulin resistance and FFA release. Insulin's suppression of adipose lipolysis is reduced with insulin 
resistance, increasing FFA circulation and amplifying insulin resistance and hyperglycemia. Cascading 
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insulin resistance is key in development of the oxidative stress, lipotoxicity and proinflammation required 
for NAFLD development 45. 
Proinflammation and Oxidative Stress - FFA amplified through insulin resistance alters hepatocyte 
mitochondrial structure and function to increase production of toxic metabolites and ROS - worsening 
mitochondrial damage and promoting hepatocyte inflammation and apoptosis 66. The Unfolded Protein 
Response (UPR) is activated in the endoplasmic reticulum through mitochondrial stress and hyperglycemia 
35. UPR triggers c-jun terminal kinase (JNK) mediated inflammation and apoptosis 67. Inflammation within 
the liver stimulates cytokine release which along with the adipocytes contribute to a proinflammatory state 
both locally in the liver, and systemically 43. 
Lipotoxicity is the accumulation of lipid intermediates in non-adipose tissue, such as the liver or skeletal 
muscle, leading to cellular dysfunction or death. In the context of NAFLD, insulin resistance and 
hyperglycaemia encourage de novo lipogenesis of FFA from carbohydrates stored in the liver 68. Then, in 
what is thought to be a protective pathway, this excess FFA is esterified into triglycerides and stored within 
the hepatocytes 39.  
1.4 Developmental origins of NAFLD and metabolic syndrome  
The ‘Developmental Origins of Health and Disease’ paradigm (DOHaD) 69,70 describes the link between 
environmental conditions during development and long term health outcomes. Heerwagen et al 71 detail 
multiple studies in which DOHaD is supported: manifestation of obesity and metabolic diseases in offspring 
of obese, overweight or diabetic mothers implicates maternal lipidemia, glycemia and inflammation as 
potential developmental origins of epigenetic modifications leading to later life metabolic complications. 
As an adaptive response, epigenetic alterations may occur in response to in utero or early developmental 
conditions. Sub-optimal conditions can result in structural and functional changes in adipose and hepatic 
tissue, and may result in a predisposition to MetS and NAFLD 72,73. 
Conversely, similar metabolic complications arise as the result of fetal undernutrition and Intrauterine 
growth restriction. By studying activation of hepatic nutrient sensor proteins in the offspring of nutrient 
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restricted rodents, Wolfe et al 74 concluded that fetal undernutrition can result in the reprogramming of 
sensor proteins. Normal nutritional load made available postnatally was then recognised as excess 
nutrition, priming pathways for hepatic lipid deposition. ‘The Thrifty Phenotype’ hypothesis 75 describes 
such responses as an adaptive measure, preparing the fetus for an environment of low nutrition. However 
when the postnatal environment is one of stable or overnutrition, these responses become maladaptive, 
contributing to insulin resistance and create a predisposition to MetS.  
Studies of low birth weight (LBW; birth weight below 2500g 76) cohorts appear to support this hypothesis. 
Human babies with LBW due to intrauterine growth restriction (IUGR) were shown to have a higher 
occurrence of pediatric NASH 77, while liver enzymes associated with hepatocellular injury were increased 
in women who were born LBW, when tested at 60-79 years of age 78. LBW and premature individuals 
undergo a compensatory rapid growth pattern after birth 79. Leunissen 80 identified the first 3 months of 
infancy to be the crucial period in which weight gain increased visceral adiposity and insulin resistance in 
young adults. In 2014 Breij et al 81 used a Fatty Liver Index (FLI) to indicate risk of NAFLD development and 
determined rapid catch up growth in LBW babies was associated with NAFLD, while slow growth catch up 
and LBW alone were not. These studies demonstrate the influence of suboptimal intrauterine environment 
on the physiology and functionality of the offspring which can result in metabolic complications during 
adulthood. The thrifty phenotype may provide insight into the mechanisms which create a predisposition 
to MetS and NAFLD in ex-premature adults. Additionally, as premature babies typically experience a 
nutrient rich environment and increased weight gain as neonates, the ‘catch up’ early developmental 
environment may constitute a predisposition to NAFLD development.  
1.5 Premature birth associations with NAFLD and metabolic 
syndrome 
 Human trials  
Metabolic abnormalities have been found to be associated with preterm birth in human trials, including 
insulin resistance 82, T2DM 10, and hypertension 5. Meta-analysis of 27 studies into preterm adult 
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associations with metabolic dysfunctions 7 indicated significant differences in term and preterm adult blood 
pressure and plasma low-density lipoprotein. A significant difference in insulin resistance between preterm 
and full term adults was not found due to conflicting results of the analysed studies. Studies on NAFLD 
association were not included for analysis. Investigations into adiposity of preterm babies at full term 
equivalent age 83 using Magnetic Resonance Imaging, found altered adipose tissue distribution, with a 
significant increase in visceral adiposity. The same research group 84 characterised an adult preterm 
phenotype in which adiposity was increased relative to full term counterparts, while BMI and other signs 
of overt obesity remained similar between the groups. Visceral abdominal adiposity was significantly 
increased in preterm-born men. As abdominal obesity is a key constituent, and possibly causal factor 85 of 
MetS, this could mean preterm men are more vulnerable to its development. This study observed young 
adults (18-27 years old), with the authors postulating that the preterm phenotype would become more 
pronounced with age, as would metabolic dysfunction. Worryingly, these prematurely born adults may be 
missing out on required cardiovascular and metabolic interventions, as the lack of overt obesity while 
carrying excessive visceral fat at a young age is not the typical presentation of MetS. 
Intrahepatocellular lipid deposition has been observed in studies of human preterm birth.  Increases have 
been found in preterms at full term equivalent age 86 and as young adults 84. Supporting the DOHaD and 
thrifty phenotype hypotheses, two studies undertaken in recent years observe the relationship between 
NAFLD and aspects of the postnatal environment of preterms. Vasu et al 87 found that lipid intake in the 
first week after preterm birth is positively correlated with hepatocellular lipid deposition at term age. Breij 
et al 88 determined accelerated weight catch-up in the first 3 months after term equivalent age was 
associated with increased FLI at 21 years of age. Both studies implicate early life nutrition as a factor of 
NAFLD predisposition.  
NAFLD disease progression evolves throughout the life course of a human. While studies have observed 
differences in predisposition and lipid deposition in infancy, investigating NAFLD progression requires 
intervals of 20-60+ years in human trials 7,32. Animal trials allow for observation of NAFLD progression to 
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occur in an expedited timeframe due to swift disease progression within a shorter lifespan. Animal trials 
also afford the opportunity to maintain consistent environments across treatment groups, limiting 
variables inherent in human trials. 
 Animal trials  
There are no published studies of NAFLD development in animal models after preterm birth, however 
animal trials in which in utero and early developmental conditions were manipulated may provide insight 
into potential pathways of NAFLD development in the preterm phenotype. High fat diets given to pregnant 
non-human primates 89, mice 90, and guinea pigs 91,92, have resulted in increased hepatic steatosis in 
offspring. Conversely, undernutrition of pregnant sheep increased steatosis in offspring, implicating a 
predisposition to NAFLD through “metabolic thriftiness”. Similarly, when testing lipogenic indices, Yamada 
et al 93 suggested IUGR rat neonates and fetuses were likely to have developed distinct metabolic pathways 
resulting in additional lipid storage.  
Parallels in the mechanisms of IUGR and undernutrition that lead to NAFLD may exist in the preterm 
phenotype, however specific investigation into the preterms association with NAFLD is required to 
understand the etiology and progression of the disease.  
1.6 Identification and characterisation of NAFLD 
 Histology techniques 
Currently, the gold standard for the diagnosis of NAFLD is histological analysis of liver biopsy 42,88,94,95. 
Specialty staining is used to visualise steatosis, inflammation and fibrosis characteristics of hepatic tissue. 
Previous NAFLD studies 40,41,95,96 have used varying combinations of; hematoxylin and eosin (H&E), sirius 
red, oil red o (ORO) periodic acid schiff (PAS), Sweet’s reticulin and Masson’s trichrome to reveal metabolite 
deposition (H&E, ORO, PAS), fibrosis (Masson’s trichrome, sirius red, Sweet’s reticulin), and inflammatory 
cell infiltration (H&E) in the liver. The use of ORO is considered far superior to H&E in determining steatosis 
and triglyceride content, especially when used in conjunction with Direct Image Analysis (DIA) 42. ORO 
adheres to lipid deposits to stain them unique to the background liver tissue, while H&E is only able to 
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show where lipid deposits previously resided as alcohol dissolves the lipid deposits during processing. Other 
spaces absent of stain (such as lumen and extracellular spaces) may be confused for lipid deposits especially 
when incorporating DIA. H&E was especially unsatisfactory in the visual determination of microvesicular 
steatosis, as droplets <15µm in size are near impossible to detect through visual determination alone.  
 Steatosis quantification 
In comparing ORO and H&E staining, Levene et al 42 found when determining the percentage of cells with 
microvesicular and macrovesicular lipid deposits visually, the sensitivity of ORO was so great that 90 - 100% 
of hepatocytes were classed as containing lipid deposits. This lead to an inability to differentiate the degree 
of steatosis when applying NAS, as all samples scored highly. However when analysing the % area of lipid 
deposits (as with DIA) and applying NAS, ORO was highly correlated with triglyceride levels. The study 
concluded with a strong recommendation that when possible ORO with DIA should be used to quantify 
steatosis. 
 Quantification of NAFLD using the NAFLD Activity Score  
To quantify the degree of NAFLD within the liver samples, an activity score is applied to histology 
specimens. Brunt et al 44 developed a NAFLD scoring system primarily to grade and stage NASH. This 
technique used the constellation of steatosis and fibrosis lesion features to determine a Necroinflammatory 
Grade and Fibrosis Score. When attempting to determine the probability of NAFLD progression to cirrhosis 
and CCH, Matteoni et al 34 defined a spectrum of states incorporated within NAFLD in addition to NASH. 
Improved methods to stage the spectrum of NAFLD were designed and validated by Kleiner et al 41. They 
proposed a NAFLD Activity Score (NAS) which used 3 criteria: Steatosis, Lobular inflammation and 
Ballooning to determine the severity of NAFLD. Fibrosis is scored separately as it is considered a result of 
NAFLD and by nature is less reversible.  
1.7 Conclusion 
Visceral obesity and insulin resistance leading to FFA flux and cytokine release result in lipotoxicity, 
oxidative stress and inflammation which manifest as steatosis, inflammation and fibrosis within hepatic 
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tissue.  Predisposition to NAFLD or NASH development is multifactorial, including genetic, epigenetic and 
developmental factors.  
Long term metabolic dysfunction as a result of premature birth is a growing area of concern as the increased 
survival rates of premature infants and their later life complications is predicted to inflate the burden on 
the national health system. The mechanisms and progression of NAFLD in the premature phenotype is not 
fully elucidated, further research is required in which the use of animal models will be a valuable tool. 
Determination of an association between prematurity and NAFLD predisposition in the guinea pig has not 
yet been investigated and is the first step in developing novel methods of recognition and intervention of 
NAFLD progression.   
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2 Methods  
2.1 Animal care and husbandry  
All animal work was performed in line with the ethical standards and guidelines laid out in Guide for the 
Care and Use of Laboratory Animals, 8th Edition, and the National Animal Ethics Advisory Commission, New 
Zealand. All work was performed with the prospective approval of the University of Otago Wellington 
Animal Ethics committee. All animals derive from the outbred colony of Dunkin Hartley guinea pigs 
maintained in the University of Otago – Wellingtons’ Biomedical Research Unit (BRU).  
 Housing  
Guinea pigs were housed within open floor pens within a temperature (22˚C) and humidity (50%) controlled 
facility. Sound insulated rooms in which the pens were contained were under a 12hour day/night light 
cycle. Floor pens were covered in pussydoo® compressed wood cat litter (Azwood Ltd, New Zealand) and 
contained cardboard boxes and tubes to provide environmental enrichment. After weaning, and if not 
enrolled in the breeding program, all guinea pigs were housed in single sex rooms.  
 Feeding 
Guinea pigs were feed a diet consistent with the nutritional needs of laboratory guinea pigs. Guinea pig 
pellets (Sharpes stock feeds, Carterton, New Zealand), hay (Sharpes Feed and Barn, Lower Hutt, New 
Zealand), fresh leafy vegetables and carrots (Jina’s Produce, New Zealand), were supplied daily.  
Millipore filtered water was supplied for drinking ad libitum. As guinea pigs are unable to synthesise vitamin 
C, dietary yield from fresh vegetables was supplemented by adding ascorbate acid (Sigma Aldrich, Sydney, 
Australia) to the water supply at a dose of 1.2g/L.  
 Breeding 
Guinea pigs enrolled into the BRU’s breeding programme are housed in 6 separate harems consisting of a 
single boar and multiple (4 – 15) sows to ensure outbreeding in the colony. Female offspring enrolled as 
breeders are systematically assigned to a harem (lineage) to which they were not born. New stock sourced 
from external guinea pig facilities is brought in to the breeding programme every 3 years to limit inbreeding.  
 Post - partum mating  
As breeding sows are housed with males throughout their oestrous cycle post-partum mating is integrated 
to give a reliable conception date of subsequent litters. As dams enter oestrous immediately after giving 
birth, allowing the dam to remain in the harem for 24 hours after delivery allows a short window for 
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conception for the dam’s next litter. Upon confirmation of pregnancy the gestational age and due date of 
the forthcoming litter is then known.  
 Confirmation of pregnancy through ultra-sound 
All breeding sows receive an abdominal ultrasound weekly to check for pregnancy. To prepare for the 
ultrasound, hair is removed from the sow’s abdominal region with hair clippers (Heinger, Switzerland). The 
ultra sound is administered by a trained technician at the BRU using a SonoSite ultrasound (Fuji Film, 
Australia). An estimate of litter size can be eluded from ultrasound 4 weeks into the pregnancy. 
 Selection and randomisation of dams for study 
Only dams who conceived during post- partum mating were enrolled into this study. Dams were randomly 
selected to be enrolled for term or preterm delivery upon confirmation of pregnancy.  
 Term delivery and postnatal care  
 Vaginal birth of term pups 
Dams randomly selected to deliver full term (control) pups received no manipulation, allowing spontaneous 
delivery at 69 days gestation. From 55 days gestation until birth, pregnant dams were weighed and their 
pelvic symphysis measured daily, with observation twice daily. Within 12 hours of delivery, pups were 
weighed, sexed, and biometric measurement taken (See 2.2 Collection of Biometric data ). 
 Postnatal care of term pups 
Pups and dams were re-homed together into the ‘maternity ward’ (a smaller pen allowing the pups easier 
access to their mother) where they will receive postnatal care until weaning. At weaning (day 21), pups 
were housed within a wood shavings (Wholesale Landscapes, Nelson, New Zealand) lined cage, which they 
will share with no more than 5 weaned pups until 28 days old.  
 Preterm delivery and postnatal care  
 Inducing vaginal birth of preterm pups 
Dams assigned to deliver preterm pups underwent pharmacological induction of labour at 62 days 
gestation. To stimulate lung maturation in the premature pup, dams received Betamethasone (1mg/kg; 
Merck, Sharp, & Dohme, New Zealand) injected subcutaneously (lml luer-lock™ syringe (Terumo, 
Philippines), 32g x 1" needle (Terumo) 48 hrs and 24 hrs prior to induction. Preterm labour was induced 
pharmaceutically with Aglepristone (10mg/kg, Provet, New Zealand) injected subcutaneously (10mg/kg; 
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1ml luer-lock™ syringe, 32g x 1" needle) 24hrs and 1hr prior to induction to terminate pregnancy and 
oxytocin (3IU/kg; Provet,) injected intramuscularly (lml luer-lock™ syringe, 36g x ½" needle into alternating 
quadriceps of the dam to stimulate uterine contractions. Oxytocin injections were repeated every ½ hour 
for the first hour of the induction process, then every 15 minutes until delivery of the first pup. Oxytocin 
was then administered at 10 minute intervals following delivery of each pup or placenta. Oxytocin 
administration continued until all pups and placentas have been expelled. The dam is then placed in 
incubator with pups for observation. 
 Resuscitation of preterm pups  
Upon birth the pup was dried and tactile stimulation applied with a hand towel, once breathing or gasping 
was observed, pups received continuous positive airway pressure (CPAP) respiratory support, which was 
administered at a 30:70 ratio of 02 and medical air (BOC gasses, New Zealand) at a rate of 5L/min and 
titrated to 100% 02 as necessary to achieve adequate oxygenation. This was delivered to pups through a 
small mask held tightly over the nose and mouth to create a seal (Neopuff Infant T-piece resuscitator, Fisher 
& Paykel Healthcare, New Zealand), with positive end-expiratory pressure (PEEP) of 5cmH20 to establish 
and maintain functional residual capacity (Figure 5a). When required, intermittent positive pressure 
ventilation was provided at a rate of 60 breaths per minute with peak inspiratory pressures of 12cmH20 for 
90 seconds or until consistent independent breathing was established and maintained. Once adequate 
respiratory function was achieved pups were further dried and placed into a towel lined cage within a 
Dräger 8000 human incubator (Drägerwerk AG & Co., Lübeck, Germany) set to 33˚C with 35% humidity. 
Supplemental oxygen was delivered to the incubator at 1L/min for the initial 12 hours. 
 Postnatal care of preterm pups 
Approximately 1 hour after birth - once respiratory support was no longer required, pups were weighed, 
sexed, and their biometric measurements and blood sugar levels taken (See 2.3.4 Blood sugar level 
readings). To prevent dehydration, subcutaneous saline was administered (lml luer-lock™ syringe, 32g x 1" 
needle) to pups 2 and 10 hours after birth or when signs of dehydration were observed (minimal urine 
output, reduced skin turgidity). 
Hand feeding of the pups began approximately 2 hours after birth (Figure 5c). Milk supplement was 
warmed to approx. 37˚C and administered orally with a 1ml syringe (Terumo). The amount of supplement 
given was dependent on the pup's interest in the food, typically pups consumed <0.5ml at birth increasing 
to 2 – 3ml by term equivalent age.  Details on the time, quantity and type of supplement given was 
recorded. As the pups were housed with their mother during this time, maternal milk gradually became 
the dominant source of nutrition as the pups became stronger and developed the ability to suckle.  
18 
 
Prior to each feeding (Table 1), pups were weighed and stimulated to evacuate their bowels and bladder. 
A cotton bud (Cotton tips, Protec) is used to apply lubricant (KY Jelly, Johnson and Johnson, USA) in a 
repetitive circular motion to the pup’s anogenital region (Figure 5d). Weights and evacuations are recorded.  
Neonate pups remained in the incubator with their dams for 3-4 days post-delivery (Figure 5b). 
Temperature and humidity were titrated to achieve adequate body temperature and cages were changed 
daily to ensure a clean environment. During this time pups are closely monitored as the non-ambulatory 
pups are at risk of suffocation (through the dam pinning down her pups) and asphyxiation (from aspiration 
of food post-feeding). 
Once pups are able to adequately maintain body temperature, pups and dam are moved from the incubator 
to an ambient environment (usually 3-4 days after delivery). The towel lining of the cage is replaced with 
wood shavings (Wholesale Landscapes, Nelson, New Zealand) once the pups are ambulatory. Upon 
reaching term equivalent age (TEA; 7 days after delivery; CPNA day 0) pups were rehomed to the ‘maternity 
ward’ alongside other dams and their litters, where they remained until weaning at CPNA Day 21. From 
TEA onwards, there is no difference in the treatment of term and preterm pups.   
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Table 1: Preterm pup feeding schedule 
Corrected postnatal age (Days)  Supplement Feeding Interval 
-7 (birth) Colostrum 2 hourly 
-6 Guinea pig milk  3 hourly 
-5 Guinea pig milk  3 hourly 
-4 50:50 guinea pig milk and apple baby food  6 hourly* 
-3 50:50 guinea pig milk and apple baby food 6 hourly* 
-2 50:50 guinea pig milk and apple baby food 8 hourly* 
-1 50:50 guinea pig milk and apple baby food 8 hourly * 
0 (TEA) No feeding unless weight is lost   
Colostrum (Wombaroo Food Products, Adelaide, Australia), Guinea Pig milk (Wombaroo Food Products), 
Apple babyfood (Watties, New Zealand). 














Figure 5: Postnatal care of preterm pups (A) A newborn preterm pup receiving resuscitation support. (B) Incubated dam with 
preterm pups, shortly after delivery. (C) A preterm pup, -4 days of age being feed with milk supplement. (D) Stimulation of 




2.2 Collection of Biometric data  
All pups were weighed daily on an electronic scale (Vibra SJ, Shinko Denshi, Japan) and measurements of 
Crown - Rump Length (CRL), Hock-toe (HT) and Hindlimb Length (HL) are taken twice weekly on days -7 & -
4 (preterms only)  and CPNA days 0, 4, 7, 10, 14, 17, 21 and 28 with a flexible tape measure (Liberty®, 
London, UK) (See Appendix 7.1, Page 97, Figure 31). Postnatal weight gain, adiposity, and growth rates 
were determined through transformation of the individual’s anthropometric measurements.  
 Fractional weight gain (FWG)  
A measure of average daily weight within a given period of time. Calculated using the method outlined by 
Patel et al 97. FWG was calculated for the first 7 days, (Day -7 to Day 0 for preterms, Day 0 – Day 7 for terms) 
and for the postnatal period (CPNA day 0 – CPNA day 21 for both preterms and terms). To exclude initial 
postnatal weight loss from the preterm period, FWG was calculated only for the days within the 7 day 
period in which weight was not lost. 
Equation 1: Fractional Weight Gain 
𝑭𝑾𝑮(𝒎𝒈/𝒈 𝒑𝒆𝒓 𝒅𝒂𝒚)  =  [𝟏, 𝟎𝟎𝟎𝒙 𝒍𝒏(𝑾𝒏/𝑾𝟏)  ]   /    (𝑫𝒏 − 𝑫𝟏)  
Where: 
Wn = weight at end time point (g) 
W1 = weight at start time point (g) 
Dn = last time point of period (days) 
D1 = first time point of period (days) 
 
 Ponderal Index (PI) 
An estimate of adiposity in relation to length.  Calculated for time points at which measurements were 
taken (Days -7, -4, (prems only) 0, 4, 7, 10, 14, 17, 21 and 28.). The sum of a guinea pig’s Crown-Rump 
Length (CRL) and Hind Limb (HL) was used as an approximation of the animal’s height.  
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Equation 2: Ponderal Index 
𝑃𝐼 (𝑘𝑔/𝑚3)  =  𝑊 /𝐿3 
Where:  
W = weight (kg) 
L = total length (m)  
   = CRL + HL 
 
2.3 Collection of metabolic data  
The following techniques were employed as an indicator of the metabolic function of the treatment groups. 
Tracking alterations in fasted BSL throughout the guinea pigs life and in response to a glucose challenge 
can indicate disruptions in insulin sensitivity and glucose metabolism. Plasma samples were retained for 
paired insulin and amino acid assay at a later date.  
 Longitudinal fasted blood sugar levels 
Blood sugar levels and blood samples were taken weekly on days -7 (preterms only at 1 and 10 hours post-
birth, non-fasted, prior to feeding) and at CPNA day 0, 7, 14, 21 and 28 following a 4 hour fasting period.  
 Oral glucose tolerance test  
Oral glucose tolerance tests (GTTs) were administered on CPNA day 28 after 4 hours of fasting. Animals 
were maintained under heat lamps and the temperature of the room was maintained at 30˚C to ensure 
circulation of blood in guinea pig extremities.  Baseline blood samples and blood sugar levels were collected 
prior to an oral dose of glucose (1000mg/kg). Blood collection and blood sugar levels were then taken 
30mins, 1hr, 2hrs and 3hrs post glucose dose. 
 Blood collection 
Guinea pigs were swaddled within a towel to restrain. Aural veins were pricked with CareSens 28G lancets 
(Pharmaco Ltd, Auckland, New Zealand), blood was allowed to form a small bead upon the ear, before 
collecting with a microvette (Sarstedt, Germany). In some cases, gentle pressure was applied to the guinea 
pig’s ear to encourage blood flow. Full microvettes (0.3ml) were centrifuged at 4000rpm for 15 minutes. At 
least 100ml of plasma was extracted from each sample and stored at -80 ˚C. 
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 Blood sugar level readings 
Midway through blood collection (See, 2.3.3: Blood collection) blood was collected on a CareSens N Testing 
strip (Pharmaco) and assessment of blood sugar levels was carried out using CareSens N Glucometer 
(Pharmaco).  
 GTT analysis  
For each animal, fasted blood sugar levels in response to a GTT administered at CPNA 28 days were graphed 
against time to create a dose response curve (Figure 6). Graphed baselines were adjusted to the animal’s 
baseline BSL. Area under the Curve (AUC), peak height and delta peak height (the difference between 
baseline BSL and peak height) were analysed for each individual.  
At each time point of the GTT concurrent plasma samples were collected for paired insulin assay. Radio 
Immuno Precipitation Assay (RIA) is to be performed by Professor David Kennaway at the University of 
Adelaide. This protocol is currently being optimised.  
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Figure 6: Example of an individuals plotted glucose tolerance test 
 
Figure 6: Example of an individuals plotted glucose tolerance test - An example of an individual’s GTT plotted against time– 
Baseline fasted BSL is the BSL measured prior to glucose dose – represented by dashed blue line. Absolute peak is the highest BSL 
reached – represented by the purple line.  peak is the highest BSL reached minus the baseline BSL – represented by the red line. 





2.4 Post mortem collection of tissues 
 Anaesthesia  
Guinea Pigs were euthanized on Day 28 prior to tissue collection. To anesthetise the animal ketamine 
(40mg/kg, PhoenixPharm, New Zealand) and medetomidine (Domitor®, 0.5mg/kg, Pfizer Animal Health, 
New Zealand) were injected in to the intraperitoneal cavity (IP) via a single 1ml luer-loc™ syringe and G32 
x 1"needle. To ensure appropriate level of anaesthesia toe pinch and eyelid reflexes were tested.   
 Measurements 
Post-mortem measurements (Head length, nose-rump, crown-rump length, hind-limb, hock-toe, head 
circumference, neck circumference, chest circumference, abdominal circumference) were taken post 
anaesthesia using a flexible tape measure.  
 Terminal blood collection 
Approximately 5ml of blood was collected prior to post mortem via cardiac punch. A 10ml luer-loc™ syringe 
was used with a 22g x ½" precisionglide™ needle (BD, Singapore) to draw blood from the heart. Blood was 
placed into 10ml EDTA vacutainers® (BD) and centrifuged (4C, 4000rpm for 12 minutes). Plasma, buffy 
coat and red blood cells were separated and stored at –80 ˚C.  
 Euthanasia  
1ml of Pentobarbital (Provet) was administered by cardiac injection using a 10ml luer-loc™ syringe with a 
22g x ½" precisionglide™ needle (BD). Death was confirmed by lack of heartbeat ahead of post mortem 
collection.  Secondary death measures (decapitation and perforation of the diaphragm) were also 
performed.  
 Tissue collection 
All dissection was performed with surgical instruments including skin scissors, internal scissors, non-
toothed tweezers, scalpel, and scalpel blade (ProSciTech, Australia). All tissues were split into fixed and 
frozen samples. Frozen tissues were snapped frozen in liquid nitrogen and stored at -80 ˚C. Tissues for 
paraffin sectioning were fixed in 10% Neutral buffered formalin (Labserv) overnight at 4 ˚C, before being 
rinsed and stored in phosphate buffer (7.4.1, Page 100) at 4˚C until processed for histology.  
 Liver collection and processing 
A midline incision was made through skin and tissue layers from the upper chest to lower abdomen. This 
incision was then extended laterally to allow access to the body cavity. The liver was dissected away from 
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the body and weighed. The lower right lobe of the liver was dissected, placed in a 50 x 60mm resealable 
bag (OfficeMax®, New Zealand) and snap frozen in liquid nitrogen. The left lower lobe was excised and 
formalin fixed within a plastic cassette and 80ml specimen container (Interlab, New Zealand) (See appendix 
7.3: Liver dissection and sampling, Page 99). 
 Visceral adipose tissue collection and processing 
Visceral adipose tissue (VAT) surrounding the kidneys was dissected and weighed. VAT from the right 
kidney was snap frozen and VAT from the left was formalin (10% buffered neutral formalin) fixed within a 
plastic cassette and 80 ml specimen container. Both samples were retained for potential future analysis.  
 Subcutaneous adipose tissue collection and processing 
Subcutaneous adipose tissue was sampled from dorsocervical fat pad atop the shoulder blades of the 
guinea pig. The skin above the fat pad was removed to allow access, and the fat pad dissected out and 
weighed The fat pad was then bisected through the midline, the right side snap frozen, the left formalin 
fixed within a plastic cassette and 80ml specimen container. Both samples were retained for potential 
future analysis.  
2.5 Histology  
 Tissue for paraffin sectioning  
 Specimen preparation 
To blind histological analysis of the tissue samples, each subject was assigned a random number 
(random.org – random sequence generator). 
From the formalin fixed liver tissue, a 5mm thickness cross section through the liver lobe was sampled. 
Tissue from the widest part of the lobe was excised (See appendix 7.3, Page 99) using a scalpel, and placed 
into a small histosette (Interlab) labelled with the subjects assigned random number.    
 Tissue processing  
To prepare the tissue for paraffin sectioning, the tissue was dehydrated using alcohol, cleared of the alcohol 
through replacement with xylene, and infiltrated with paraffin wax. This process was performed 




Table 2: Tissue Processing Protocol 
Ethanol (Labserv), xylene (Labserv), Paraplast Plus® paraffin wax (McCormick™ Scientific, USA) 
*See solution appendix: 7.2.2, Page 86 
 Embedding 
Using a Tissue-Tek® Embedding centre (Sakura™) each sample was embedded within a (30x20mm) mould 
with paraffin wax heated to 60 ˚C. The embedded sample was cooled on a Tissue-Tek® Cryoconsole 
(Sakura™), before removal from the mould. 
 Microtomy 
4μm thick tissue sections were cut using a Leica RM2235 microtome (Leica Biosystems, New Zealand) with 
feather S35 blades (Feather Safety Razor co., Japan) and floated on a 48˚C flotation waterbath (Thermo 
Scientific, New Zealand) for collection onto StarFrost® microscope slides (Knittel Glass, Germany). 
For each sample, 6 serial sections were taken from 3 tissue depths (levels) approximately 800μm apart 
(Table 3).  
Reagent Duration Temperature Process  
Formalin 2 hours 37 ˚C Fixation 
70% ethanol* 1 hour 37 ˚C Dehydration 
70% ethanol* 1 hour 37 ˚C Dehydration 
90% ethanol*  1 hour 37 ˚C Dehydration 
100% ethanol  1 hour 37 ˚C Dehydration 
100% ethanol 1 hour 37 ˚C Dehydration 
100% ethanol 1 hour 37 ˚C Dehydration 
100% ethanol 1 hour 37 ˚C Dehydration 
Xylene 1 hour 37 ˚C Clearing of ethanol  
Xylene 1 hour 37 ˚C Clearing of ethanol 
Paraffin wax 30 minutes  60 ˚C Infiltration of wax  
Paraffin wax 30 minutes  60 ˚C Infiltration of wax 
Paraffin wax 30 minutes  60 ˚C Infiltration of wax 
Paraffin wax  30 minutes  60 ˚C Infiltration of wax 
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Table 3: Order of sections cut and the stains they were used for.  









1x H&E  1x H&E  1x H&E  
2x spares 2x spares 2x spares 
1x trichrome 1x trichrome 1x trichrome 
1x spare 1x spare 1x spare 
1x sudan black (5μm) 1x sudan black (5μm) 1x sudan black (5μm) 
1x spare (5μm) 1x spare (5μm) 1x spare (5μm) 
 
 Staining  
2.5.1.5.1 Haematoxylin and Eosin (H&E) 
Staining was batched according to level to ensure distribution of potential batch effects across all samples. 
All batches were stained using the same solutions following the Otago Wellington Pathology Departments 
protocol (Table 4). Stained sections were mounted in Tissue-Tek® Glas Mounting Media (Sakura® Finetek) 
and coverslipped (22 x 40, Menzel-Gläser, Thermo Scientific). 
Table 4: Haematoxylin & Eosin Protocol 
Reagent Duration Process  
Xylene 5 minutes Deparaffinization   
Xylene 5 minutes Deparaffinization   
100% ethanol  3 minutes Clearing of xylene 
100% ethanol 3 minutes Clearing of xylene 
70% ethanol* 3 minutes Rehydration 
Running H20 3 minutes Rehydration  
Haematoxylin* 12 minutes Staining of nuclear detail 
H20 x1 dip Remove excess haematoxylin  
Acid Alcohol * x2 dips Differentiation of haematoxylin 
Running  H20 10 minutes Blueing of haematoxylin 
Eosin* 4 minutes  Staining of cytoplasm  
Running H20 x5 dips Remove excess Eosin  
70% ethanol* 3 minutes Dehydration 
100% ethanol  3 minutes Dehydration 
100% ethanol 3 minutes Dehydration 
Xylene 5 minutes Clearing of alcohol 
Xylene 5 minutes Clearing of alcohol 
*See solution appendix: 7.4.2, Page 100 
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2.5.1.5.2 Masson’s Trichrome  
Staining was batched according to level to ensure distribution of potential batch effects across all samples. 
Batches were stained following a protocol modified from IHCWorld 98 (Table 5). Stained sections were 
mounted in Tissue-Tek® Glas Mounting Media and coverslipped. 
Table 5: Masson’s trichrome staining protocol 
Reagent Duration Process  
Xylene 5 minutes Deparaffinization   
Xylene 5 minutes Deparaffinization   
100% ethanol * 3 minutes Clearing of xylene 
100% ethanol* 3 minutes Clearing of xylene 
70% ethanol* 3 minutes Rehydration 
Running H20 3 minutes Rehydration  
Bouin’s solution* 1hour at 60 ˚C Fixation 
Running H20 10 minutes Remove excess Bouin’s solution 
Weigert’s Iron haematoxylin* 10 minutes Nuclear staining  
Running  H20 10 minutes Blueing of haematoxylin 
Distilled  H20 x5 dips Wash 
Biebrich scarlet-acid fuchsin* 12 minutes Cytoplasmic staining 
Distilled  H20 x5 dips Wash 
Phosphomolybdic-phosphotungstic acid * 12 minutes  Differentiation  
Light green in 1% acetic acid* 20 minutes Staining of collagen  
Distilled  H20 x5 dips Wash 
70% ethanol* 3 minutes Dehydration 
100% ethanol 3 minutes Dehydration 
100% ethanol 3 minutes Dehydration 
Xylene 5 minutes Clearing of alcohol 
Xylene 5 minutes Clearing of alcohol 





 Tissue for frozen section  
 Specimen preparation and cryosectioning  
From frozen liver tissue, a 5mm thickness cross section through the liver lobe was sampled. Tissue from 
the widest part of the lobe was excised (See appendix 7.3, Page 99) using a coping saw (Fuller, Canada) and 
placed into small plastic bag labelled with the subjects assigned random number. 
Tissue was embeded within Tissue-Tek® O.C.T. Compound (Sakura®) within a Tissue-Tek® cryostat 
(Sakura®) set at -20C. 12μm sections were cut using feather s35 blades and adhered to polycine® coated 
slides (Labserv).  
 Oil red O Staining  
All samples were stained within the same batch following an oil red o protocol adapted from Melehem et 
al 99 and Bancroft et al 100 (Table 6). Stained sections were mounted in Shandon Immuno-Mount™ (Thermo 
Scientific) and coverslipped. 
Table 6: Oil red O staining protocol 
*see solutions appendix: 7.4.4 , Page 101 
 Histological analysis  
 Microscopy and photography  
Microscopy was performed on an Olympus BX51 microscope with images captured using a Olympus DP20 
mounted camera (Olympus, New Zealand). 
Five fields of view at 100x or 200x magnification were photographed from each section (3 sections for each 
sample). These 5 fields of view were taken in the same general areas of each section (See appendix 7.3, 
Page 99) Randomization within these areas was ensured by positioning the slide upon the stage 
macroscopically - therefore ensuring microscopic details of the slide would not influence the area selected 
for sampling.  
Reagent Duration Process  
Formalin  20 seconds Fixation   
Oil Red O * 5 minutes Lipid staining   
Harris’s Haematoxylin * 15 seconds Nuclear staining 
Running  H20 30 minutes Blueing of haematoxylin & 
washing away excess ORO 
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 Quantification of hepatic physiology using NAFLD Activity Score (NAS) 
To quantify the presence of NAFLD features (steatosis, inflammation, fibrosis) a NALFD Activity Score (NAS) 
was applied to each sample. The scoring applied in this study was adapted from Kleiner et als’ system 
devised for quantifying the severity of NAFLD presentation in humans 41. Adaptions were based upon Liang 
et als’ murine and rodent NAS validation 95, and incorporated to increase sensitivity of detection as the 
NAFLD presentation was expected to be minor in our relatively young subjects. 
2.5.3.2.1 Steatosis  
Hepatocyte steatosis was assessed on H&E stained sections photographed at 100x magnification. Lipid 
droplet % coverage of each field of view was assessed using ImageJ version 1.51n (National Institutes of 
Health, USA) by measuring area fraction with colour threshold (Hue: 227 – 71, Saturation: 81 – 255, 
Brightness: 0 – 255). The average % coverage of the 5 fields of view of each sample was scored based on 
Kleiner et al’s criteria (Table 7). 
Table 7: Kleiner et als’ NAS steatosis score criteria 
Score Lipid droplet % area coverage 
0 < 5% 
1 5 – 33% 




Lobular Inflammation was assessed on H&E stained sections photographed at 100x magnification. 
Inflammatory foci in each field of view were counted to quantify inflammation. Inflammatory foci were 
considered to be a cluster (not a row) of 5 or more inflammatory cells within a 100 μm2 area. Foci larger 
than 100 μm2 were counted as a single foci. Inflammatory cells surrounding portal triads were excluded, as 
portal inflammation was not assessed. The average of the 5 fields of view of each level was scored based 
on Liangs et al’s rodent NAS criteria to give a score for the sample level and two inflammation scores were 
calculated for each subject:  
1. The scores of the 3 levels of a given sample were then averaged to give an inflammation score for 
the subject.  




Table 8: Liang et als’ Inflammation score system 
Score  Number of foci (at 100x mag) Severity 
0 <0.5  Normal 
1 0.5 – 1 Slight 
2 1 – 2  Moderate 
3  > 2 Severe 
   
 
Hepatocyte ballooning was assessed on H&E stained sections photographed at 100x magnification. 
Hepatocytes were described as ‘ballooned’ when enlarged beyond twice their original size, with flocculent 
cytoplasm. Ballooned hepatocytes in each field of view were counted to quantify inflammation. ‘Few’ was 
considered to be 10 or less ballooned cells within the field of view.  
 
Table 9: Kleiner et als’ Hepatocyte ballooning score system 
Score  Extent Details 
0 None  
1 Few ballooned cells Rare but definite ballooned hepatocytes 
2 Many balloon cells / prominent ballooning    
 
2.5.3.2.3 Fibrosis  
Hepatic fibrosis was assessed on Masson’s trichrome stained sections photographed at 100x magnification. 
The presence and location of collagen staining was used to determine the presence and severity of 
pathologic fibrosis using the fibrosis scoring system described by Kleiner et al (Table 10). 
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Table 10: Kleiner et als’ Fibrosis score system 
Score Fibrosis location and extent 
0 None 
1 Perisinusoidal or periportal 
1A Mild (‘delicate’), Zone 3, Perisinusodial  
1B Moderate (‘dense’), Zone 3, Perisinusodial 
1C Portal / Periportal 
2 Perisinusodial and Portal / Periportal  
3 Bridging fibrosis 
4 Cirrhosis 
 
2.6 Hepatic metabolomics analysis 
 Extraction 
Amino acid analysis was performed by the Analytical Facility for Bioactive Molecules, The Hospital for Sick 
Children, Toronto Canada. Ground tissue was weighed out and a solution of 1:1 water : methanol was 
added to yield 25mg/mL. Samples were then homogenized and kept on ice. An equivalent of 5mg of 
homogenized tissue was added to an Eppendorf tube with an acylcarnitine internal standard (IS) mixture 
(NSK-B, Cambridge Isotopes, USA) and an amino acid IS mixture (Arginine-13C6, ADMA-d7, citrilline-d7, 
glutamic acid-d2, ornithine-d7, and leucine-d10, Cambridge Isotopes and CDN Isotopes, USA). Samples and 
standard mixtures were then acidified with 60µL of 0.1% formic acid and then protein was precipitated 
using 1mL of formic acid in acetonitrile. Tubes were then vortexed and centrifuged at 10,000g for 10 
minutes at 4C. Supernatants were transferred to conical glass tubes and the remaining pellet in the 
Eppendorf was re-suspended in an additional 1mL 0.3% formic acid in acetonitrile and vortexed and 
centrifuged again. The combined supernatants were dried under gentle flow nitrogen gas. Samples and 
standards were derivatized with 100µL butanolic-HCL3N for 30 minutes at 65C. Solvent was then removed 
under gentle flow nitrogen gas and samples were reconstituted in 200µL MPS and transferred to auto 
sampler vials. 10µL of the reconstituted sample was diluted 50x in the same solution for amino acid 
analysis.  
 Liquid chromatography-tandem mass spectroscopy (LC-MS/MS) 
Extracted samples were injected onto Kinetex HILIC 50 x 4.6mm 2.6µ, column (Phenomenex, USA) 
connected to an Agilent 1290 HPLC system attached to a Q-Tarp 5500 mass spectrometer (AB Sciex, USA). 
Injected samples were eluted with a gradient of mobile phases MPA: 90/10 f mM ammonium formate pH 
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3.2/acetonitrile and MPB: 10/90 5mM ammonium formate pH 3.2/acetonitrile. The diluted samples were 
eluted with a gradient of MPA starting at 4% for 2.5 minutes and increasing to 75% MPA until 6 minutes, 
holding at 75% MPA for 1 minute and then returning to 4% over the final 2.5 minutes Mass transitions were 
monitored for each sample and compared against known standard mass transitions for species analysed. 
Data was collected and analysed using Analyst v1.6 (AB Sciex). 
2.7 Statistical Analysis 
Statistical analysis of all data was performed using STATA version 15 (StataCorp, USA). The subjects received 
two treatments, full term birth and premature birth. Within these treatments the subjects were further 
divided into male and female groups to account for potential variation due to sexual dimorphism.  
Data distribution within the 4 groups (term males, preterm males, term females, preterm females) was 
tested with Shapiro-Wilk test for normality and Levene’s robust test for equality of variances. 
Comparisons between the four groups were made using a 2x2 factorial analysis of variance (2-way ANOVA) 
with the inclusion of interaction effects between prematurity and sex. A multi factorial design was chosen 
as it can account for a larger proportion of variability using smaller sample sizes (an ethical priority when 
using animal models) than single factor analysis allows 101. Longitudinal data was compared between 
cohorts of the same sex and assessed by random-effects GLS regression. Pearson correlations were used 
to determine strength and significance of associations between data sets. Significance was set at p<0.05. 
Prism version 7 (Graphpad Software, USA) was used to generate figures. All data is presented as mean  





3.1 Cohort mortality and assignment 
The rates of spontaneous stillbirth in the BRU’s guinea pig colony were at ~ 10%.during the study period.  
Of live born term guinea pigs at the BRU there was a 3.9% mortality rate during the birth – weaning period. 
Within the 13 term litters produced for this study there were no stillborn pups, or pup deaths (Figure 7). 
Within the 15 preterm litters produced for this study, 18.03% of the 61 preterm pups produced were 
stillborn (n=11). 8% of live born preterm pups died during the preterm period (birth – TEA) (n=4). Of the 4 
dead pups, 1 was euthanized due to significant respiratory distress, 3 were found dead - suspected to have 
been suffocated or crushed by their mother. All pups surviving the preterm period remained healthy until 
the studies end point at 28 days. 
Male and female live born pups were randomly assigned to this (NAFLD) study and other concurrent 
studies. Siblings of the same sex were not enrolled within the same study group to prevent litter effect bias 
102.  
Figure 7: Allocation and mortality of term and preterm pups  
 




3.2 Biometrics  
 Weight 
As expected, preterm birth had a significant effect on birth weight, with both male and female term pups 
weighing more than their preterm counterparts (p<0.001; term females, 91.7 ± 9.7g vs. preterm females 
72.41 ± 4.7g, and term males, 95.3 ± 14.4g, vs. preterm males, 77.7 ± 6.5g; Figure 8a).  
Weight loss immediately following birth is well described in both term and preterm infants. In the current 
study, preterm pups lost a significantly higher proportion of their body weight than term pups (p<0.001; 
term males: 0.4 ± 0.7% lost over 0.6 ± 0.9 days vs. preterm males: 9.5 ± 3.4% over 2.9 ± 0.4 days, term 
females: 0.5 ± 1.2% over 0.4 ± 0.9 days vs. preterm females: 8.6 ± 3.5% over 2.6 ± 0.5 days; Table 11). 
Weight loss stabilised at approximately 3 days postnatal age (CPNA -5 days) in preterm animals (Table 11), 
following which both male and female preterm pups gained weight at rates comparable to that seen in 
term newborns over the first week of life (p=0.3427; term females: 59.3 ± 11.5mg/g/day vs. preterm 
females 68.2 ± 17mg/g/day; term males: 56.7 ± 14.4mg/g/day vs. preterm males 56.7 ± 9.3mg/g/day; 
Figure 10a). Over this period, preterm pups gained enough weight that there was no difference in weight 
between preterm animals at TEA and term birth weight (p=0.8204; Figure 8b). 
Weight gain from CPNA day 0 (TEA in preterm pups) to weaning was not different between preterm and 
term animals (p=0.3885;Figure 10b). Preterm birth and sex therefore had no significant effect on weight at 
CPNA day 28. On average term males and females weighed heavier than their preterm counterparts 
(p=0.0715; term females, 263.9 ± 20.9g vs. preterm females 242.9 ± 33.8g; and term males, 281.9 ± 34g, 
vs. preterm males, 264.9 ± 27.4g Figure 8C). Both term and preterm males were heavier than term and 
preterm females at weaning (p=0.0587). 
Growth trajectory was similar between term and preterm males until CPNA day 21 (weaning) (Figure 9). 
However, by CPNA day 28 significant divergence was observed, with a greater growth rate in term males 
than in preterms (p=0.003). In females, terms and preterms had similar growth rates between TEA and 
CPNA day 11. From CPNA day 12, terms and preterms began to diverge, with term females showing greater 
growth rate compared to preterms (CPNA day 12, p=0.05; CPNA day 13, p=0.04; CPNA day 14, p=0.05; CPNA 
day 15, p=0.03; CPNA day 16, p=0.01; CPNA day 17, p=0.08; CPNAd day 18, p=0.03; CPNA day 19, p=0.003; 
CPNA day 20, p=0.003; CPNA day 21, p=0.07; CPNA day 28, p=0.003; Figure 9).  
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                                             (C) 
 
Figure 8: Weight of term and preterm pups  – Solid pink bars represent term females (n=9), hashed pink bars represent preterm 
females (n=7), solid blue bars represent term males (n =10), and blue hashed bars represent preterm males (n=8). (A) Birthweight 
(B) Weight at term equivalent age (TEA) (C) Weight at CPNA day 28. All data analysed using 2-way ANOVA and presented as group 























P prematurity  < 0.01 
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Weight - CPNA 28 days
P prematurity  = NS 
P sex  = NS
P interaction = NS
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Figure 9: Weight growth rate over time of term and preterm pups 
 
Figure 9: Weight growth rate over time of term and preterm pups. Day -7 to CPNA day 28. Solid pink lines represent term females 
(n=9), dashed pink lines represent preterm females (n=7), solid blue lines represent term males (n =10), and blue dashed lines 
represent preterm males.  All data analysed with random-effects GLS regression and presented as group means ± SD. * denotes 









  Term (n=10) Preterm (n=9) 
 
Term (n=8) Preterm (n=7) 
Initial period of weight loss (days) 0.6 ± 0.9 2.9 ± 0.4* 
 
0.4 ± 0.9 2.6 ± 0.5* 
Total weight lost  0.37g ± 0.6g 7.3g ± 2.9g*  0.5g ± 1.1g 6.2g ± 2.5g* 
Weight loss (% birth bodyweight) 0.4% ± 0.7% 9.5% ± 3.4%* 
 
0.5% ± 1.2% 8.6% ± 3.5%* 
Daily weight lost  0.2g ± 0.3g 2.5g ± 0.9g*  0.3g ± 0.5g 2.4g ± 0.9g* 
 
Table 11: Postnatal weight loss of term and preterm pups– All data analysed using 2-way ANOVA and presented as mean ± SD. * 










Figure 10: Fractional weight gain of preterm and term pups– solid pink bars represent term females (n=9), hashed pink bars 
represent preterm females (n=7), solid blue bars represent term males (n=10), and blue hashed bars represent preterm males 
(n=8). (A) FWG during first 7 days of life when initial period of weight loss is excluded (terms day 0 -7, preterms day-7 – 0). (B) FWG 
from CPNA day 0 - day 28. All data analysed using 2-way ANOVA and presented as group means ± SD. * denotes significance of 
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Birth length (CRL) was significantly affected by prematurity, male and female term pups were both longer 
than their preterm counterparts (p<0.001; term females, 122 ± 10mm vs. preterm females 111 ± 4mm, and 
term males, 128 ± 8mm, vs. preterm males, 155 ± 6mm; Figure 11a). 
By TEA, preterm and term males had grown to be significantly longer than their female counterparts 
(p=0.0089; term males, 128 ± 8mm, vs. term females, 122 ± 10mm, preterm males, 134 ± 4mm vs. preterm 
females 125 ± 7mm, Figure 11b). Preterm male and females had both grown in length to surpass term born 
animals, although not significantly. (p=0.0724). 
Sex and prematurity had no effect on length at CPNA 28 days. Length was relatively consistent across all 
groups (prematurity p=0.4144, sex p=0.2330; term females, 192 ± 7.1mm, vs. preterm females, 190 ± 
6.9mm vs. term males, 189 ± 8.3mm vs. preterm males 186± 11mm; Figure 11c). 
Linear growth trajectory was not affected by prematurity overall in male (p=0.100) or female (p=0.378) 
cohorts. However, within the males the preterm growth curve deviated from the terms’ from CPNA day 14 
until the end of the study period (CPNA day 14, p=0.002; CPNA day 17, p=0.037; CPNA day 21, p=0.007; 
CPNA day 28; p=0.003; Figure 12).It is not known if this deviation would continue after the juvenile 
period/the studies endpoint. Female preterms deviated from their term counterparts even earlier than the 
males, displaying less CRL growth velocity than the terms from CPNA day 7 and convergence by the end of 
the study period (CPNA day 7, p=0.043; CPNA day 10, p=0.015; CPNA day 14, p=0.027; CPNA day 17, 
p=0.004; CPNA day 21, p<0.001; CPNA day 28, p=0.173; Figure 12).  
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                                          (C) 
 
 
Figure 11: Crown – Rump length of term and preterm pups. Solid pink bars represent term females (n=9), hashed pink bars 
represent preterm females (n=7), solid blue bars represent term males (n=10), and blue hashed bars represent preterm males 
(n=8). (A) Birth Crown-Rump length (CRL) (B) CRL at term equivalent age (TEA) (C) CRL at CPNA day 28 (D) Growth Rate (CRL) - day 
-7 to CPNA day 28. All data analysed using 2-way ANOVA and presented as group means ± SD. * denotes significance of prematurity 




































Figure 12: Linear growth over time of term and preterm pups 
 
Figure 12: Linear growth over time of term and preterm pups.  Linear (CRL) growth rate - day -7 to CPNA day 28. Solid pink 
lines represent term females (n=9), dashed pink lines represent preterm females (n=7), solid blue lines represent term males (n 
=10), and blue dashed lines represent preterm males. All data was analysed with random-effects GLS regression and presented as 
group means ± SD. * denotes significance of prematurity p < 0.05  
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 Adiposity as assessed by ponderal index 
Surprisingly average adiposity at birth was slightly greater in preterm pups, although this was not significant 
(p=0.1178, term females, 22.8 ± 3.6kg/L3 vs. preterm females 23.5 ± 1.1kg/L3, and term males, 20.7± 2kg/L3, 
vs. preterm males, 22.8 ± 2.7kg/L3; Figure 13a). 
There was a significant effect of prematurity at TEA, with adiposity of preterms reducing to below that of 
the terms (p=0.0289; term females, 22.8 ± 3.6kg/L3 vs. preterm females 20.4 ± 0.9kg/L3, and term males, 
20.7± 2kg/L3, vs. preterm males, 19.4 ± 1.3kg/L3; Figure 13b). On average male adiposity remained lower 
than that of females pups (p=0.0697).  
By the studies endpoint at CPNA day 28, adiposity was comparable between term females, term males, 
preterm males and preterm female (prematurity p=0.1012, sex p=0.6474; term males, 21.9 ± 1.4kg/L3, 
preterm males 21.7 ± 2.1kg/L3 and term females, 20.9 ± 2.1kg/L3, vs. preterm females, 23 ± 1.3kg/L3; Figure 
13c). 
Preterm females differed in their overall velocity of adipose development compared to term females 
(p=0.012) with an altered adipose development curve at all time points (CPNA day 3, p=0.044; CPNA day 7, 
p=0.007; CPNA day 10, p=0.012; CPNA day 14, p=0.028; CPNA day 21, p<0.001; CPNA day 28, p<0.001; 
Figure 14). On the other hand, prematurity in the males did not result in an overall effect on adipose 
development velocity (p=0.81), However divergence from term males did occur between their trajectories, 
with convergence by CPNA day 28 (CPNA day 3, p=0.001; CPNA day 10, p=0.034; CPNA day 14, p=0.001; 
CPNA day 21, p<0.004; CPNA day 28, p=0.111; Figure 14).  
44 
 





                                                    (C)  
 
 
Figure 13: Adiposity (ponderal index) of term and preterm pups. Solid pink bars represent term females (n=9), hashed pink bars 
represent preterm females (n=7), solid blue bars represent term males (n=10), and blue hashed bars represent preterm males 
(n=8). (A) Ponderal Index (PI) at birth (B) PI at TEA (C) PI at CPNA day 28. All data analysed using 2-way ANOVA and presented as 
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Figure 14: Adiposity development over time of term and preterm pups 
 
Figure 14: Adiposity development over time of term and preterm pups - day -7 to CPNA day 28.Solid pink lines represent term 
females (n=9), dashed pink lines represent preterm females (n=7), solid blue lines represent term males (n =10), and blue dashed 
lines represent preterm males.  All data analysed with random-effects GLS regression and presented as group means ± SD. * 




3.3 Metabolism  
 Weekly fasted blood sugar Levels 
As described in humans, birth fasted BSL was significantly affected by prematurity, with lower BSLs 
recorded for male and female preterm pups than terms. (p<0.001; term females, 6.2 ± 1.1mmol/L vs. 
preterm females 4.4 ± 1.6mmol/L and term males, 6.4 ± 0.9mmol/L, vs. preterm males, 4.5 ± 1.8mmol/L; 
Figure 15a). 
Upon reaching TEA, preterm metabolism had over-compensated by increasing fasted BSL to be significantly 
greater than the fasted BSL of the term cohorts. (p<0.001; term females, 6.2 ± 1.1mmol/L vs. preterm 
females 7 ± 1.6mmol/L and term males, 6.4 ± 0.9mmol/L, vs. preterm males, 8.5 ± 0.4mmol/L; Figure 15b). 
BSL of term pups also increased in during their first 7 days of life, however this was not to the same extent 
seen in the preterms (p<0.001; term females increased 0.8 ± 1.7mmol/L vs. preterm females 3.7 ± 
2.5mmol/L, term males increased 1.2 ± 1.6mmol/L, vs. preterm males, 4.0 ± 1.8mmol/L; Table 12). 
Neither prematurity nor sex had a significant effect on fasting BSL at CPNA day 7, as metabolism of the 
preterm animals had stabilised. On average term females had lower BSL than term males (term females, 
6.9 ± 1.6mmol/L vs. term males, 7.5 ± 1.8mmol/L,) while BSL of the preterm cohorts were similar (preterm 
females, 6.6 ± 1.1mmol/L vs. preterm males, 6.4 ± 1.1mmol/L) (p=0.7087; Figure 15c). 
Final fasted BSLs were obtained at CPNA day 28 where no significant differences were found between any 
of the cohorts. (p=0.0565; term females, 7.6 ± 0.5mmol/L, vs. preterm females, 7.3 ± 0.6mmol/L and term 
males, 7.9 ± 1.1mmol/L, vs. preterm males, 7.1 ± 0.5mmol/L; Figure 15d). 
Both male and female preterms displayed deviations in overall BSL trajectory when compared to their term 
counterparts (male p<0.001, female p<0.001). BSL movement was altered in the preterms at all time points 
(males; CPNA day 7, p<0.001; CPNA day 14, p<0.001; CPNA day 21, p=0.001; CPNA day 28, p<0.001, females; 
CPNA day 7, p=0.002; CPNA day 14, p=0.004; CPNA day 21, p<0.001; CPNA day 28, p p=0.004; Figure 16). It 
is not known if convergence would have occurred beyond the study period/ the juvenile stage.   
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Figure 15: Weekly fasted blood sugar levels of term and preterm pups. Solid pink bars represent term females (n=9), hashed pink 
bars represent preterm females (n=7), solid blue bars represent term males (n =10), and blue hashed bars represent preterm males. 
(A) Birth blood sugar level (BSL) (B) BSL at TEA (C) BSL at CPNA day 7  (D) BSL at CPNA day 28 (E) Weekly BSL - day -7 to CPNA day 
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Figure 16: Blood sugar levels over time of term and preterm pups 
 
Figure 16: Blood sugar levels over time of term and preterm pups. Day -7 to CPNA day 28. Solid pink lines represent term females 
(n=9), dashed pink lines represent preterm females (n=7), solid blue lines represent term males (n =10), and blue dashed lines 
represent preterm males. All data analysed with random-effects GLS regression and presented as group means ± SD. * denotes 
significance of p < 0.01.  
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Table 12: Change in fasted blood sugar level during the 1st 7 days of life in term and preterm 






  Term (n=10) Preterm (n=8) 
 
Term (n=9) Preterm (n=7) 
Change in BSL over 1st 7 days of life (mmol/L) 1.2 ± 1.6 4.0 ± 1.8*  0.8 ± 1.7 3.7 ± 2.5* 
 
Table 12: Change in fasted blood sugar level during the 1st 7 days of life in term and preterm pups.- First 7 days of life occurs 
from CPNA day -7 to day 0 in preterms, day 0 – day 7 in term pups.  All data analysed using 2-way ANOVA and presented as mean 




 Glucose tolerance test 
In addition to the fasted BSL taken at CPNA day 28, BSLs in response to a glucose tolerance test (GTT) were 
recorded and plotted (Figure 6, Page 24). There was no significant effect of sex or preterm birth on the 
pups’ baseline, absolute peak, or -peak BSLs during the GTT, neither was there an effect on AUCs 
generated from the GTT (Figure 17). Preterm birth and sex had no significant effect on peak BSL, (p=0.1802; 
term males, 19 ± 2.5mmol/L, vs. preterm males, 18.3 ± 3.6mmol/L and term females, 17.6 ± 1.5mmol/L vs. 
preterm females, 15.7 ± 1.4mmol/L; Table 13). The same pattern was exhibited in -peak BSL (p=o.6013; 
term males, 11 ± 1.8mmol/L, vs. preterm males, 11 ± 3.4mmol/L and term females, 9.9 ± 2mmol/L vs. 
preterm females, 8.3 ± 0.9mmol/L; Table 13). 
One male preterm was excluded from GTT analysis as the final BSL reading at 180 minutes was not 
collected. Of the 33 individuals with a complete GTT, 6 did not return to their baseline level within the time 
frame of the GTT. These individuals were term females (x3), preterm females (x2) and a term male (x1). 
These individuals were included in all GTT analyses as their exclusion did not affect statistical analyses.  
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Figure 17: Blood Sugar levels in response to glucose tolerance test at CPNA 28 days  
 
Figure 17: Blood Sugar levels in response to glucose tolerance test at CPNA 28 days– solid pink lines represent term females (n=9), 
dashed pink lines represent preterm females (n=7), solid blue lines represent term males (n=10), and blue dashed lines represent 
preterm males (n=7). All data analysed using 2-way ANOVA and presented as group means ± SD. 
 





  Term (n=10) Preterm (n=7) 
 
Term(n=9) Preterm (n=7) 
Baseline blood sugar level (mmol/L) 8 ± 1.1 7.1 ± 0.5 
 
7.8 ± 0.5 7.5 ± 0.7 
Absolute peak blood sugar level (mmol/L) 19 ± 2.5 18.3 ± 3.6 
 
17.6 ± 1.5 15.7 ± 1.4 
δ peak blood sugar level (mmol/L) 11 ± 1.8 11 ± 3.4 
 
9.9 ± 2 8.3 ± 0.9 
Area under curve  913 ± 145 988 ± 330 
 
832 ± 230 807 ± 229 
# of individuals which didn’t return to base 
line after 180mins  
3 2  1 0 
Table 13: Average glucose tolerance test characteristics of term and preterm pups - All data analysed using 2-way ANOVA and 
presented as mean ± SD. 
  




























Blood sugar levels in resonse to GTT
CPNA 28 days 
Term Males (n = 10)
Term Females (n = 9)
Preterm Males (n = 7)
Preterm Females (n = 7)
P prematurity  = NS 
P sex  = NS
P interaction = NS
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3.4 Physiology at CPNA 28 days 
Key organs in the biological pathway of NAFLD development - the liver, visceral fat and subcutaneous fat, 
were weighed and compared between treatment groups at the studies endpoint, CPNA day 28.  
There was no effect of sex or prematurity on the weights of visceral and subcutaneous fat relative to body 
weight, consistent with our calculated measure of adiposity (PI) at CPNA day 28 (Figure 13c). On average, 
visceral fat deposition was consistent across all groups (prematurity p=0.9852, sex p=0.1069; term males, 
0.2 ± 0.1%, vs. preterm males, 0.2 ± 0.1% vs. term females, 0.1 ± 0.07% vs. preterm females 0.2 ± 0.06%; 
Table 14) as were subcutaneous deposits (prematurity p= 0.5464, sex p=0.5145; term males, 0.8 ± 0.2%, 
vs. preterm males, 0.8 ± 0.2% vs. term females, 0.8  ± 0.1% vs. preterm females 0.8  ± 0.2%; Table 14). 
Livers were significantly heavier (relative to body weight) in both male and female preterm animals 
(p=0.0449; term males, 3.3 ± 0.2%, vs. preterm males, 3.6 ± 0.2% and term females, 3.3 ± 0.3% vs. preterm 
females 3.7 ± 0.4%; Table 14). But were not different between males and females (p=0.9191). 
 Hepatic physiology 
To determine if preterm livers deviated in other aspects of physiology, steatosis, inflammation and fibrosis 
of the liver was quantified and analysed at CPNA day 28.  
Preterm birth had a significant effect on hepatic steatosis with higher NAS steatosis scores for male and 
female preterm pups than terms pups (p=0.0428; term females, 0.44 ± 0.53, vs. preterm females, 0.71 ± 
0.49 and term males, 0.3 ± 0.48 vs. preterm males 0.75 ± 0.46; Figure 18a, Figure 19). Sex had no significant 
effect (p=0.7515).  
The average number of inflammatory foci, viewable in a x100 magnification field of view (FOV) was not 
significantly different between preterm and term cohorts. The number of inflammatory foci was especially 
variable in the male preterm cohort (prematurity p=0.4823, sex p=0.4086; term females, 0.13 ± 0.26 
foci/FOV vs. preterm females 0.07 ± 0.10 foci/FOV, and term males, 0.06 ± 0.09 foci/FOV, vs. preterm males, 
0.05 ± 0.07 foci/FOV; Figure 12b, Figure 20).  
Hepatocyte ballooning, an indication of advanced inflammation was not observed within any samples 










  Term (n=10) Preterm (n=8) 
 
Term (n=9) Preterm (n=7) 
Liver (% body weight) 3.3% ± 0.2% 3.6% ± 0.2%* 
 
3.3% ± 0.3% 3.7% ± 0.4%* 
Visceral Fat (% body weight) 0.2% ± 0.1% 0.2% ± 0.1% 
 
0.1% ± 0.07% 0.2% ± 0.06% 
Subcutaneous Fat (% bodyweight) 0.8% ± 0.2% 0.8% ± 0.2% 
 
0.8% ± 0.1% 0.8% ± 0.2% 
 
Table 14: Organ weights relative to body weight of term and preterm pups at CPNA 28 days- All data analysed using 2-way ANOVA 












Figure 18: Physiological characteristics of term and preterm liver tissue at CPNA 28 days. Solid pink bars represent term females 
(n=9), hashed pink bars represent preterm females at (n=7), solid blue bars represent term males (n=10), and blue hashed bars 
represent preterm males (n=8). (A) Average NAS steatosis score (0 -3) at CPNA 28 days (B) Average number of inflammation foci / 



























P prematurity  = 0.0428 
P sex  = NS
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P prematurity  = NS 
P sex  = NS














































Figure 19: Examples of oil red o stained hepatic steatosis observed in terms and preterms. - Lipid droplets (red) among 
hepatocytes (light blue) and hepatocyte nuclei (dark blue).  (A) Image from a test sample containing the least amount of steatosis 
observed. Lipid droplets covered 0.112% of total image area receiving a NAS steatosis score of 0.  (B) Image from a test sample 
representative of the average % steatosis coverage in term males. Lipid droplets covered 3.564% of total image area and was given 
a NAS steatosis score of 0.  (C) Image from a test sample representative of the average % steatosis coverage in preterm males. Lipid 
droplets covered 4.603% of total image area and was given a NAS steatosis score of 0.  (D) Image from a test sample containing 
the most amount of steatosis observed. Lipid droplets covered 13.23% of total image area receiving a NAS steatosis score of 1. All 














Figure 20: Examples of H&E stained hepatic inflammation and steatosis in terms and preterms. White blood cells (dark purple) 
among hepatocytes (pink) and hepatocyte nuclei (light purple).  (A) Hepatic tissue free from inflammatory foci, photographed at 
x100 magnification.  (B) Inflammatory focus (circled in black) within hepatic tissue, 100x magnification.  (C) A large inflammatory 
focus (circled in black) within hepatic tissue, 100x magnification. Insert: Close up of the inflammatory focus at 200x magnification. 
White blood cells comprising the focus are clearly visible  (D) Steatotic hepatocytes characterised by round vacuoles (white) where 
lipids existed prior to tissue processing, 100x magnification Insert: A close up of the same steatotic tissue at 200x magnification. 














Figure 21: Examples of hepatic tissue stained with Masson’s trichrome.  Collagen fibres (green) surrounding vascular and ductal 
lumen (white) among hepatocytes (pink).  A, B, C, D) Images from test samples in which perisinusoidal, periportal or portal fibrosis 
was not observed. Vascular collagen surrounding portal triads is clearly stained green. All images are of 4µm thick sections taken 




3.5 Hepatic molecular changes 
 Essential and conditionally essential amino acids 
Preterm birth had a significant effect on hepatic arginine concentration, with lower levels in preterms 
compared to terms (p<0.001; term females, 0.024 ± 0.005nmol/mg, vs. preterm females, 0.016 ± 
0.005nmol/mg, term males, 0.049 ± 0.019nmol/mg, vs. preterm males 0.016 ± 0.005nmol/mg; Figure 22a). 
Arginine concentration was also significantly affected by sex (p= 0.0094) with greater levels of arginine in 
term males than term females. There was a significant interaction between sex and prematurity 
(p=0.0107). Both male and female preterms had lower levels of arginine than the terms, however the effect 
of prematurity was greater in the males. In addition, an inverse correlation in hepatic lipid accumulation 
and arginine was observed (r=-0.4835, p=0.0106; Figure 23a). 
Hepatic concentration of histidine was not significantly affected by preterm birth or sex. Concentrations 
were similar across all groups (prematurity p=0.6025, sex p=0.8856; term females, 6.3 ± 1.3, preterm 
females, 6.5 ± 0.8nmol/mg, term males, 6.7 ± 1.3nmol/mg and preterm males 6.0 ± 0.9nmol/mg; Figure 
22b). Histidine was not significantly correlated with hepatic steatosis (r=-0.3241, p=0.1140; Figure 23b). 
Hepatic lysine concentration was not significantly affected by prematurity or sex, however preterm females 
had greater levels of lysine on average than term females (preterm females, 6.0 ± 1.3nmol/mg, vs. term 
females, 5.5 ± 1.2nmol/mg;), and preterm males had lower levels of lysine on average than term males 
(term males, 6.6 ± 1.6nmol/mg and preterm males 5.4 ± 0.9nmol/mg.), p=0.4115 (Figure 22c), although 
there was no significant interaction between sex and prematurity (p=0.0687). Lysine was found to be 
inversely correlated with accumulation of hepatic lipids (r=-0.4584, p=0.0162; Figure 23c). 
Concentration of methionine within the liver was not significantly affected by prematurity or sex, 
(prematurity p=0.0811, sex p=0.4664; term females, 1.0 ± 0.2nmol/mg vs. preterm females 0.8 ± 
0.3nmol/mg, and term males, 0.9 ± 0.2nmol/mg, vs. preterm males, 0.8 ± 0.2nmol/mg; Figure 22d). 
Methionine was not correlated with hepatic steatosis (r=-0.0541, p=0.7929; Figure 23d). 
Preterm birth significantly affected phenylalanine concentration, decreasing hepatic concentrations, 
especially in the male preterm cohort (prematurity p=0.0169, sex p=0.4538; term females, 0.8 ± 
0.3nmol/mg vs. preterm females 0.7 ± 0.2nmol/mg, and term males, 0.9 ± 0.4nmol/mg, vs. preterm males, 
0.4 ± 0.1nmol/mg; Figure 22e) There was no association found between phenylalanine concentration and 
hepatic deposition (r=-0.1090, p=0.5809; Figure 23e).  
Hepatic concentration of threonine was not significantly affected by prematurity or sex (preterm females, 
6.7 ± 1.1nmol/mg, vs. term females, 5.9 ± 2nmol/mg, and term males, 7.6 ± 1.9nmol/mg vs. preterm males 
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6.1 ± 1.3nmol/mg) (prematurity p=0.5808, sex p=0.3620; Figure 22f). This was not a significant interaction 
(p=0.0905). Threonine concentration was inversely correlated with hepatic lipid deposition (r=-0.5678, 
p=0.0031; Figure 23e). 
Tryptophan in the liver was altered significantly by preterm birth with decreased concentration in both 
male and female preterm animals (p=0.0242; term females, 0.62 ± 0.16nmol/mg, vs. preterm females, 0.46 
± 0.07nmol/mg and term males, 0.69 ± 0.18nmol/mg vs. preterm males 0.53 ± 0.22nmol/mg; Figure 22g0). 
There was no correlation between tryptophan concentration and quantification of hepatic lipids (r=-0.1154, 
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Figure 22: The effect of preterm birth on essential amino acid concentration in the liver at CPNA 28 days. Solid pink bars represent 
term females, hashed pink bars represent preterm females, solid blue bars represent term males, and blue hashed bars represent 
preterm males.  (A) Arginine concentration – term females n=7, preterm females n=5, term males n=9, preterm males n=8. (B) 
Histidine concentration – term females n=7, preterm females n=6, term males n=7, preterm males n=6.  (C) Lysine concentration 
– term females n=8, preterm females n=6, term males n=8, preterm males n=6. (D) Methionine concentration – term females n=5, 
preterm females n=6, term males n=8, preterm males n=8. (E) Phenylalanine concentration – term females n=8, preterm females 
n=6, term males n=8, preterm males n=7. (F) Threonine concentration – term females n=6, preterm females n=6, term males n=7, 
preterm males n=7. (G) Tryptophan concentration – term females n=8, preterm females n =7, term males n=8, preterm males n=8. 




































Figure 23: The correlation between hepatic lipid deposition and essential amino acid 
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Figure 23: The correlation between hepatic lipid deposition and essential amino acid concentrations in the liver at CPNA 28 
days. (A) Arginine (n=27). (B) Histidine (n=25) (C) Lysine (n=27) (D) Methionine (n=26) (E) Phenylalanine (n=28). (F) Threonine 
(n=25) (G) Tryptophan (n=29). All data analysed using Pearson correlation. * denotes significance of correlation, p < 0.05.   
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  Branched chain amino acids 
Preterm birth significantly decreased hepatic concentration of isoleucine in male and female preterm 
animals compared to terms (p = 0.0319; term females, 2.7 ± 0.9nmol/mg vs. preterm females 2.4 ± 
0.4nmol/mg; and term males, 3.2 ± 1.1nmol/mg, vs. preterm males, 2.2 ± 0.4nmol/mg Figure 24a). 
Isoleucine was also inversely correlated with hepatic lipid accumulation (r=-0.6030, p=0.0009; Figure 25a). 
Hepatic leucine concentration was significantly altered by prematurity, with depletion of leucine observed 
in the preterms (p=0.0174; term females, 6.0 ± 1.8nmol/mg, vs. preterm females, 5.1 ± 1.2nmol/mg and 
term males, 6.8 ± 1.9nmol/mg, vs. preterm males, 4.7 ± 0.8nmol/mg; Figure 24b). Leucine was inversely 
associated with hepatic lipid deposition (r=-0.5943, p=0.0011; Figure 25b). 
As with the other branched chain amino acids (BCAAs), preterm birth significantly affected hepatic valine 
concentration with significantly lower levels of valine in preterms compared to terms (p=0.0365; term 
females, 4.4± 1.2nmol/mg, vs. preterm females, 3.9 ± 0.4nmol/mg, and term males, 4.9 ± 1.5nmol/mg, vs. 
preterm males, 3.5 ± 0.7nmol/mg; Figure 24c). A moderate inverse association between hepatic lipid 




Figure 24: The effect of preterm birth on branched chain amino acid concentrations in the liver 
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Figure 24: The effect of preterm birth on branched chain amino acid concentrations. Solid pink bars represent term females, 
hashed pink bars represent preterm females, solid blue bars represent term males, and blue hashed bars represent preterm males. 
(A) Isoleucine concentration – term females n=8, preterm females n=6, term males n=8, preterm males n=6. (B) Leucine 
concentration – term females n=9, preterm females n=8 term males n=7, preterm males n=8. (C) Valine concentration – term 
females n=8, females n=7, term males n=8, preterm males n=6. All data analysed as 2-way ANOVA and presented as group means 





































Figure 25: The correlation between hepatic lipid deposition and branched chain amino acid 
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Figure 25: The correlation between hepatic lipid deposition and branched chain amino acid concentrations in the liver at CPNA 
28 days.. (A) Isoleucine (n=27) (B) Leucine (n=27) (C) Valine (n=27). All data analysed using Pearson correlation. * denotes 




  Non-essential amino acids  
Preterm birth had a significant effect on hepatic concentration of alanine with significantly lower levels of 
alanine in preterms animals compared to terms (p <0.001; term females, 25.9 ± 7.2nmol/mg, vs. preterm 
females, 17.71 ± 6.1nmol/mg, and term males, 32.4 ± 6.2nmol/mg, vs. preterm males, 19.0± 3.3nmol/mg; 
Figure 26a). Alanine concentration was not significantly altered by sex (p=0.0927). Hepatic lipid 
accumulation was not significantly correlated with alanine levels (r=-0.3388, p=0.0778; Figure 27a). 
Citrulline concentration was not significantly affected by preterm birth or sex, (prematurity p=0.3114, sex 
p=0.3705; term females, 0.62 ± 0.22nmol/mg, vs. term males, 0.60 ± 0.25nmol/mg and preterm females, 
0.63 ± 0.23nmol/mg and preterm males 0.63 ± 0.23nmol/mg; Figure 26b). There was no significant 
interaction between sex and prematurity (p=0.5914), and no association with hepatic lipid deposition (r=-
0.0126, p=0.9483; Figure 27b).  
Cysteine hepatic concentration was significantly altered by premature birth, with a large increases in 
concentration observed in male and female preterms (p<0.001; term females, 1.44 ± 1.44nmol/mg, vs. 
preterm females, 3.43 ± 0.98nmol/mg, and term males, 0.51 ± 0.22nmol/mg, vs. preterm males, 2.55 ± 
0.76nmol/mg; Figure 26c). Cysteine concentration was also significantly altered by sex, with even greater 
increase seen in the females cohorts (p for sex =0.0191). Cysteine concentration was positively correlated 
with lipid accumulation within the liver (r=0.6152. p=0.0006; Figure 27c). 
Preterm birth significantly depleted hepatic glycine concentration when compared to term cohorts 
(p=0.001; term females, 110.0 ± 19.9nmol/mg, vs. preterm females, 95.0 ± 8.9nmol/mg, term males, 134.4 
± 29.1%, vs. preterm males 91.1 ± 9.3nmol/mg; Figure 26d). Hepatic glycine concentration and lipid 
deposition were inversely associated (r=-0.6352, p=0.0004; Figure 27d). 
Ornithine concentration in the liver was unaffected by prematurity or sex (prematurity p=0.7368, 
sex=0.0795; term females, 8.2 ± 3.5nmol/mg vs. term males, 11.4 ± 2.8nmol/mg, preterm females, 9.2 ± 
1.6nmol/mg vs. preterm males 9.7 ± 2.4nmol/mg; Figure 26e). A correlation between hepatic lipid 
accumulation and ornithine was not observed (r=-0.0396, p=0.8414; Figure 27e). 
Preterm birth and sex both significantly affected hepatic proline concentration with lower levels of proline 
in both preterm and female cohorts compared to the male term cohort (prematurity p=0.0220, sex 
p=0.0311; term females, 8.6 ± 1.6nmol/mg, vs. preterm females, 8.1 ± 1.3nmol/mg, and term males, 13.81 
± 4.8nmol/mg, vs. preterm males, 8.4 ± 2.1nmol/mg; Figure 26f). Additionally, proline was inversely 
associated with hepatic lipid accumulation (r=-0.4917, p=0.0107; Figure 27f). 
Hepatic serine concentration was significantly altered by prematurity with lower serine levels in preterm 
cohorts (p=0.0100; term females, 29.1 ± 9.1nmol/mg vs. preterm females, 25.1 ± 3.1nmol/mg and, term 
67 
 
males, 36.7 ± 9.7nmol/mg vs. preterm males, 25.4 ± 2.4nmol/mg; Figure 26g). Lipid deposition within the 
liver was inversely associated with serine levels (r=-0.6823, p=0.0001; Figure 27g). 
Prematurity had a significant effect on tyrosine concentration in the liver with significantly lower levels of 
tyrosine in preterm animals (p=0.0009; term females, 3.5 ± 1.1nmol/mg, vs. preterm females, 2.6 ± 
0.5nmol/mg, and term males, 3.8 ± 1.0nmol/mg, vs. preterm males, 2.4 ± 0.3nmol/mg; Figure 26h). A 





Figure 26: The effect of preterm birth on Non-essential amino acid concentrations in the liver at 





















































Figure 26: The effect of preterm birth on Non-essential amino acid concentrations in the liver at CPNA 28 days. Solid pink bars 
represent term females, hashed pink bars represent preterm females, solid blue bars represent term males, and blue hashed bars 
represent preterm males.  (A) Alanine concentration – term females n=8, preterm females n=6, term males n=8, preterm males 
n=7.  (B) Citrulline concentration – term females n=8, preterm females n=6, term males n=8, preterm males n=8.  (C) Cysteine 
concentration – term females n=7, preterm females n=6, term males n=8, preterm males n=7.  (D) Glycine concentration – term 
females n=8, preterm females n=6, term males n=8, preterm males n=7.  (E) Ornithine concentration – term females n=7, preterm 
females n=6, term males n=8, preterm males n=8.  (F) Proline concentration – term females n=6, preterm females n =7, term males 
n=8, preterm males n=7. (G) Serine concentration – term females n=8, preterm females n=6, term males n=8, preterm males n=6.  
(H) Tyrosine concentration – term females n=8, preterm females n=6, term males n=8, preterm males n=6.  All data analysed using 





































Figure 27: The correlation between hepatic lipid deposition and non-essential amino acid 























Figure 27: The correlation between hepatic lipid deposition and non-essential amino acid concentrations in the liver at CPNA 28 
days. (A) Alanine (n=28) (B) Citrulline (n=29) (C) Cysteine (n=27) (D) Glycine (n=27) (E) Ornithine (n=28)  (F) Proline (n=26) (G) Serine 




 Amino acid profiles of male and female preterms 
 
Figure 28: Total amino acids significantly altered with preterm birth  
 
 
Figure 28: Total amino acids significantly altered with preterm birth – grey segment represents amino acids not significantly 
altered by preterm birth, blue segment represents amino acids significantly altered in preterm males only, purple segment 
represents amino acids significantly altered in both male and female preterm animals.  
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4 Discussion  
4.1 The preterm phenotype  
 Growth  
Our study found significant alterations in preterm growth, deviating from the term phenotype (Figure 30). 
Many of these trajectories observed in our study are consistent with human preterm observations, 
however some key differences in adipose tissue development was observed. 
At birth our preterm cohort was significantly lighter and shorter than term born counterparts, as observed 
in human preterm birth 103. By TEA, weight and length had caught up to that of the terms, suggesting that 
growth of the preterms was comparable to foetal growth of the terms. However, on closer examination of 
growth during the preterm period, differences were observed in weight loss of our terms and preterms. 
Immediately after birth, preterms experienced a period of weight loss significantly greater in severity than 
the terms. This has also been observed in premature human birth and can lead to declining health without 
intervention 104. Weight gain and linear growth rates of the preterm pups were consistent overall, however 
deviations from the term phenotype were observed, including; reduced weight gain in preterm females 2 
weeks after TEA until the studies endpoint; and limited linear growth (CRL) of preterm females (TEA – CPNA 
21), and preterm males (CPNA 14 – CPNA 28). These findings are comparable to ex-preterm growth 
trajectory in humans, who were found to remain smaller than their term counterparts until at least 18 years 
of age 105. 
The finding that our preterms displayed greater adiposity at birth than terms was surprizing as adipocyte 
development has previously been described as occurring late in the 3rd trimester 106,107. Birth adiposity in 
both terms and preterms was highly variable, and maybe indicative of confounding variation in maternal 
and litter characteristics. In order to minimise the impact of litter and maternal effects, REML analysis and 
nested two-way ANOVAs should be performed, however this would require a cohort much larger than the 
current study. Throughout the study period, adiposity as assessed by ponderal index was highly vairiable in 
all cohorts. Overall, female preterms significantly diverged from term females in their adiposity 
development, however by the studies endpoint their adiposity was not significantly different from the 
other cohorts. Preterm males had extended periods of divergence from term males, however adiposity 
development was not significantly altered overall. Increased adiposity, a common complication in adult ex-
preterms which contributes to metabolic syndrome, was not observed in our relatively young pups, 
however increased adiposity development during later life (as occurs in humans) cannot be ruled out 108. 
Further research tracking adiposity into later life stages is required to definitively draw such conclusions. 
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We were unable to determine if accelerated catch up growth, a common feature in preterm human growth 
trajectory, was a factor within our preterm cohort 109. Comparisons between FWG of the terms and 
preterms were made during the first week of life, however this is not a valid comparison. To determine if 
accelerated catch up growth was a factor in our cohort, a foetal ontogeny study is required to determine 
‘normal’ foetal growth rates between GA 62 and 69 days. In humans accelerated catch up growth is likely 
due to clinical practice, where accelerated growth has historically been promoted to mitigate the effects 
(mortality and decreased cognitive function) of low birth weight 110. This practice is currently debated as 
growth acceleration, or ‘catch up growth’ has been liked to adverse metabolic and cardiovascular 
conditions development later in life.110.  
While our preterms experienced a period of initial instability, growth from TEA onwards was consistent 
with term trajectories. Males tended to be of greater weight throughout the study period, displaying the 
sexual dimorphism in growth that is expected in both guinea pigs and humans 111,112.  
      Key Findings: 
• Postnatal weight loss and growth trajectory of our preterm cohorts was consistent with human 
preterm growth.  
• By TEA, preterms had caught up to terms in weight and length, although preterm growth rates slowed 
after this catch up period.  
• Adiposity was highly variable in both term and preterm cohorts, increased adiposity associated with 
metabolic syndrome had not yet developed in our young cohort. 
 
 
 Metabolism  
Key metabolic alterations in the preterm phenotype were observed within our study. Initial fluctuations in 
our preterms fasted BSLs could result in alterations in NAFLD associated pathways, predisposing the 
preterm to NAFLD development later in life (Figure 30). Preterm animals had significantly lower fasted BSL 
at birth than terms, consistent with observations of increased hypoglycaemia in human preterm and LBW 
neonates 113,114. Hypoglycaemia in the neonate indicates dysfunction in metabolic regulatory pathways, 
with an imbalance in use and supply of glucose 115. This is possibly due to immaturity of endocrine and 
enzymatic controls in the preterm 116 and/or lack of glycogen and fat stores which develop primarily during 
the 3rd trimester. Without intervention, hypoglycaemia can result in severe neurological and growth deficits 
114. Upon reaching TEA, our preterm cohorts’ fasted BSL had risen to be significantly higher than the terms, 
a commonly described postnatal condition in preterm humans 117. Postnatal hyperglycaemia may occur 
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through immaturity of the pancreatic β cells and resistance to the insulin they produce 118. This pattern of 
hyperglycaemia following hypoglycaemia has previously been described in preterm human infants 119. We 
observed deviations in overall BSL trajectory in both male and female cohorts throughout the study period, 
indicating altered metabolism within the preterm cohort which may have altered downstream pathways 
associated with NAFLD. Harader et al’ demonstrated that hyperglycaemia exacerbated early phase NALFD 
development in mice through increased inflammatory cytokine release 120. Hyperglycaemia is also 
associated with insulin resistance which increases FFA by encouraging adipose tissue lipolysis and de novo 
lipogenesis within the liver 35. This excess in FFA is stored in the liver, resulting in increased steatosis, a 
hallmark of NAFLD 39.  
Glucose tolerance tests (GTTs) were administered at 28 days to give a clearer indication of metabolic 
function and insulin resistance in ‘early childhood’. No significant differences were found, indicating 
stabilisation of glucose homeostasis and insulin resistance (although insulin levels throughout life and in 
response to the oral GTT have yet to be assessed, and may offer some additional insight into metabolic 
function). In future, GTTs could be administered prior to ‘early childhood’ to better establish if insulin 
resistance is occurring in the preterms prior to BSL stabilisation.  
Limited circulating blood volume prevented administration of GTTs to the guinea pigs at multiple 
developmental time points. Preliminary data gathered by our group from a cohort of 6 month old term and 
preterm guinea pigs showed an effect of prematurity (p=0.02; See appendix 7.2, Page 98). This implies 
metabolic function of the preterm may fluctuate during development, with insulin resistance developing 
later in life. Potentially, metabolic function of our preterm cohort may have diverged from the terms in 
later life (after our study end point).  
      Key Findings: 
• At birth, low fasting BSL in preterms is likely due to immaturity in endocrine and enzymatic metabolic 
controls and underdeveloped glycogen and fat storage.  
• By TEA, fasted BSL of the preterm has risen significantly above the terms indicating metabolic 
dysfunction and possible insulin resistance.   






 Hepatic physiology  
The steatosis and inflammation observed in our preterm cohort was not severe enough for any of our 
subjects to be diagnosed with NAFLD in the current study. However, significant increase in steatosis 
observed in our preterm cohort can be considered a precursor marker of potential NAFLD development. 
Isolated steatosis is the first histologically observable hepatic alteration in the development of NAFLD 121. 
Increased steatosis could be the outcome of dysfunction in one of 4 mechanisms: FFA uptake, de novo 
lipogenesis, lipid oxidation or lipid exportation from the liver 37,64. Increased FFA uptake is implicated in our 
study, as fluctuating fasting BSL in our preterms may indicate insulin resistance with adipose tissue lipolysis 
and de novo lipogenesis as a result (Figure 30). 
Preterms also exhibited a slight increase in inflammatory foci, although due to variation within the groups, 
this was not a significant result. Hepatic inflammation can be caused by systemic (originating from adipose 
tissue dysfunction), or local inflammation. Hepatic steatosis occurs in an environment of excess lipid 
intermediates. These intermediates have been found to place strain on mitochondria and endoplasmic 
function resulting in cytokine release and ROS production 43. The significant but relatively low level of 
steatosis observed in our preterm cohort, may not yet be at a level in which cellular dysfunction occurs, as 
reflected by our inflammation findings. Fibrosis was not observed in any of the samples collected. This is 
unsurprising as onset occurs in response hepatocyte apoptosis resulting from steatosis and inflammation 
46. 
Our finding of increased hepatic steatosis, although relatively small, is significant especially as the pups are 
of a relatively young age. Previous human preterm studies have found increased rates of steatosis and liver 
damage in comparably older (young adult) patients 88. Further studies are required to determine if the 
increased steatosis we found during ‘early childhood’ would continue to develop, stabilise or ameliorate 
with age. Likewise, inflammation may increase with age, and fibrosis may develop later in life.  
      Key Findings: 
• NAFLD was not present during ‘early childhood’ in any of our subjects, however steatosis, a precursor 
to its development was. 





 Hepatic molecular alterations 
Amino acids can be categorised as essential or non-essential, dependant on the body’s ability to synthesise 
the amino acids from precursor molecules. Essential amino acids must be obtained from dietary sources. 
Conditionally essential acids, ordinarily biosynthesised, may require dietary supplementation during 
periods of physiological stress, such as premature birth. Amino acid deficiency or excess and can result in 
a broad range of pathologies in all aspects of physiological function. Depletions may be caused by 
biosynthesis dysfunction or insufficient intake, while excess accumulation may be the result of an inability 
to break down or convert the molecule.  
Similarly to earlier studies, we observed amino acid depletions associated with liver damage and lipid 
deposition, and an increased concentration of cysteine which inhibits lipid clearance from the liver, in our 
preterm offspring (Figure 30).   
 Cysteine, serine, glycine, and threonine   
Increased levels of cystine (the more stable, oxidised dimer form of cysteine) have been observed in plasma 
and urine of patients with liver damage 122. Walshe et al found increased excretion of cystine was directly 
related to increased fasting plasma levels of cystine suggesting impairment in amino acid metabolism 
associated with liver damage. Excessive dietary intake of cysteine was found to promote fatty liver, while 
methionine (not significantly altered in our study) and choline were preventative 123,124. Cysteine, 
dramatically increased in the preterm cohorts of our study, is a conditional amino acid. It has been 
suggested that cysteine is not synthesised in preterms, however Riedijik et al found no evidence of this in 
their human preterm cohort 125. Furthermore, a downstream metabolite of cysteine, hydrogen sulphide, 
has been found to be raised in preterm newborns 126. A pathway proposed by Toohey et al suggests 
excessive cystine oxygenation results in sulfur sulfane (So) - binding intermediates which deplete free So, 
preventing lipoprotein export from the liver, suggesting a key role in hepatic lipid accumulation (steatosis) 
and NAFLD development 124. Conversely, methionine is thought to increase available So therefore acting as 
a lipotropic agent. Cysteine is further implicated as a contributing factor to the NAFLD predisposition 
observed in our preterms, by the positive correlation we observed between hepatic lipid accumulation and 
hepatic cysteine concentration. Further research is required to determine the mechanism by which 
cysteine is increased in the preterms and the role it plays in hepatic lipid deposition.  
Serine, a non-essential amino acid is a precursor molecule of cysteine and was depleted in preterms of the 
current study. Supplementation of L-serine has resulted in reduced hepatic lipid accumulation in rats, which 
was described as a potential result of accelerated homocysteine metabolism 127. Glycine and cysteine share 
serine as a key precursor to their biosynthesis. The increased cysteine observed in our preterms may 
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therefore be a contributing factor in the preterms glycine deficiency, as the serine ordinarily used in glycine 
production could have been seconded to the cysteine synthesis pathway. Threonine, an essential amino 
acid required for the biosynthesis of serine and glycine, was not altered within our preterm cohort, however 
lower levels were moderately correlated with the increased hepatic steatosis observed in our study. This 
correlation could simply be a reflection of threonine’s role in cysteine and serine synthesis, which are 
directly associated with hepatic lipid accumulation 124,127. As threonine is an essential amino acid, it maybe 
the limiting factor when dietary intake cannot keep up with the demand increased cysteine synthesis 
imposes, resulting in reduced serine and glycine levels.  
 Leucine, isoleucine, valine and alanine 
Serum levels of branched chain amino acids (BCAAs) have been found to be decreased with liver damage, 
and supplementation of BCAAs in rats with chronic liver damage showed reduction in hepatic apoptosis 
94,95. Additionally, patients with chronic liver disease receiving BCAA supplementation had improved insulin 
response and beta cell function, indicating a potential role of BCAAs in insulin homeostasis. This protective 
function of BCAAs may partly be due to their ability to induce activation of genes involved in ROS inhibition 
and hepatic oxidation repair 128. The three essential BCAAs—leucine, isoleucine and valine, were all 
significantly depleted in our preterm cohorts, furthermore their depletions were moderately correlated 
with increased hepatic steatosis. It is unclear if BCAA depletion is a result or outcome of liver damage, 
however preterms have been identified as being at risk of receiving inadequate levels of BCAAs for two 
potential reasons: inadequate nutrition reserves due to shortened gestation, and lowered ability to absorb 
nutrients due to an underdeveloped gastrointestinal tract 94,97.  
Furthermore, alanine, significantly reduced in our studies preterms, is synthesised in the body from 
pyruvate and BCAAs. Potentially the depletion of valine, leucine and isoleucine observed in the male 
preterms of our study has prevented adequate production of alanine. As with the BCAAs, alanine was found 
to reduce liver damage in rats 129. 
 Tryptophan 
Tryptophan, an essential amino acid with antioxidant properties and sourced from maternal milk was 
depleted in our preterm cohorts 130. In 2014 two studies were published highlighting tryptophan as a 
potential treatment option for NALFD. Ritze et al demonstrated NAFLD attenuation in mice receiving 
tryptophan orally 131; and Celinski et al observed lowered levels of hepatic triglyceride and inflammatory 
cytokines within NAFLD patients receiving tryptophan and melatonin supplementation 132. Potentially, 
remedying the tryptophan deficit observed in the preterms of the current study could have a similar 
ameliorative effect on the increased steatosis we observed.  
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 Arginine and proline  
Arginine, found to be depleted only in preterm males of the current study has been described as a 
conditionally essential amino acid in preterms 133.This discrepancy among male and female preterms 
observed in the current study may indicate a sexual dimorphism in the ability to self-synthesise arginine 
while under stress, with males having less success. This is contrary to a study by Ruzafa et al, where male 
mice had higher concentrations of arginine in muscle, plasma and kidney tissue when dietary arginine was 
restricted 134. Unfortunately, Ruzafas study was not designed to reflect arginine concentration when under 
physiological stress, so the sexual dimorphism they observed may not translate to the preterm phenotype, 
although it is interesting to note differing capabilities of arginine synthesis between sexes exists. Arginine 
supplementation has been found to increase hepatic blood flow and decrease steatosis in rats 135. This is 
likely due to the arginine’s role as precursor in the synthesis of nitric oxide which acts as a vasodilator within 
the liver 136. 
Proline, reduced in our preterm cohorts, was shown by Tomlinson et al to be the key precursor molecule 
for arginine synthesis in preterm neonatal pigs and humans 137,138. Therefore reduced proline may 
contribute to the preterm males lowered ability to synthesise arginine. Tomlinson et al’s study also 
highlights alternate pathways of arginine synthesis. Potentially males and females have differing ability to 
use these pathways, which could contribute to the sexual dimorphism in arginine concentration observed 
in our study, however further research is needed to come to such a conclusion.  
 Tyrosine and phenylalanine 
Tyrosine, an essential amino acid, was depleted in our preterm males and was moderately inversely 
correlated with hepatic lipid accumulation. Phenylalanine, a non-essential amino acid synthesised in the 
body from phenylalanine was similarly depleted in preterm males, although not correlated with steatosis.  
      Key Findings: 
• Increased cysteine may inhibit lipid exportation from the liver, resulting in hepatic steatosis. 
• BCAA depletion is associated with liver damage and oxidation. Supplementation with BCAAs 
ameliorates liver damage.  
• Many of the amino acids found depleted in our study reduced hepatic lipid deposition when 





Figure 30: Proposed biological pathway of NAFLD development in the preterm  
 
 
Figure 30: Proposed biological pathway of NAFLD development in the preterm. Alterations to the preterm phenotype observed 
in the current study identified in green. In blue, the amino acids found to be significantly altered in our preterm cohorts, alongside 




4.2 Strengths of the model  
 The guinea pig as a model of premature birth 
The suitability of animal models varies depending on the mechanisms, anatomy and responses the study 
wishes to manipulate and observe. Rodent models are well established, but key differences in gestational 
development 139 may lead to inaccurate translation when modelling premature birth. The use of sheep, 
although well described as a model of prematurity 140, are divergent from humans in their placentation 141. 
Guinea pigs share similarities in antenatal development, parturition and placentation with humans 142. 
Development of the premature guinea pig paradigm 143, has enabled modelling of long term health 
outcomes of premature birth. Previous studies employed caesarean section 144, requiring the termination 
of the mother and eliminating the possibility for maternal-infant interaction. Berry et als’ innovation of 
medically induced labour, maintains maternal stimulation of the offsprings’ sympathetic adrenergic 
systems preventing variation in cardiometabolic function resulting from a lack of maternal care 145. 
Neonatal nutritional intake is also more accurately represented as the offspring are able to suckle with 
postnatal survival of the mother.  
 The guinea pig as a model of hepatic function  
Guinea pigs have previously been established as a suitable model for studying hepatic function and lipid 
metabolism in the human due to key similarities in hepatic enzyme activity 146, lipoprotein transport, 
synthesis and storage, and response to dietary intervention 147–149. Guinea pigs have also been assessed on 
their ability to mimic human inflammation (a key component in NAFLD), and atherosclerosis (a potential 
outcome of NAFLD). Fernandez & Volek demonstrated the ability of guinea pigs to develop atherosclerosis 
when fed a high cholesterol diet and validated guinea pigs as a model to study inflammatory response 
during atherosclerosis development 150. 
Currently there is no validation of a NAS specific to guinea pig presentation. In 2014 Laing et al set out to 
validate Kleiner et als’ NAS system for the use rodent trials. Comparing human and murine liver biopsies, 
discrepancies in the manifestation of NAFLD were observed, such as the relative rarity of hepatocellular 
ballooning within murine samples 95. As the guinea pig maybe a closer representation of the human hepatic 
system than the murine model 151, our quantification took hepatocellular ballooning into consideration. 
Hepatocellular ballooning was not observed in the current study, however this may be due to the limited 
severity of NAFLD within our cohort rather than its absence in the guinea pig model. Validation of a guinea 
pig NAS system using a spectrum of NAFLD severity would be worthwhile. 
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4.3  Limitations and considerations  
 Use of corticosteroids prior to preterm birth  
The introduction of corticosteroids into the premature birthing paradigm may have introduced additional 
confounding variables as our term cohort was not exposed to antenatal corticosteroid treatment. However, 
the incorporation of such pharmaceutical intervention is imperative to the paradigm as offspring would not 
survive preterm delivery at this gestational age without it (Dyson et al, unpublished data).  
Betamethasone, administered to encourage lung maturation in the preterm, is classed as a glucocorticoid 
due to it’s role in glucose metabolism. Betamethasone has been found to be associated with neonatal 
hypoglycaemia 152, which may account for the lowered birth BSL observed within our preterm cohort. As a 
group, glucocorticoids act on the liver and adipose tissue to regulate glucose homeostasis 153. 
Glucocorticoids have also been found to effect pathways key in the development of NAFLD; increasing 
lipolysis within adipose tissue, and stimulation of hepatic gluconeogenesis 154–156. It is not yet known if 
administration of betamethasone alone effects these pathways, however this research implicates 
betamethasone as a potential contributing variable to the increased steatosis observed within our preterm 
cohort.  
Betamethasone is routinely administered in cases where there is a risk of preterm birth, so its use in our 
paradigm is analogous to the clinical setting 143,157. The ability to elucidate if NAFLD development is the 
result of preterm birth or the clinical treatment administered in preterm cases is an important distinction, 
therefore our research group currently has a study underway which aims to elucidate potential alterations 
betamethasone may have on guinea pig growth and metabolism. Understanding the effect of 
corticosteroids, including betamethasone will allow us to account for potential treatment variation in 
future studies. 
 Use of anaesthetics to euthanize  
Pentobarbital, medetomidine and ketamine are routinely used for anesthetisation and euthanasia in 
animal studies, however may alter hepatic chemistry due to the livers role in metabolising these drugs. 
Overmyer et al observed changes in key liver metabolomics, especially with ketamine use and therefore 
recommended the use of isoflouraine for anesthetisation 158. However, in the metabolomics observed in 
this study (amino acids) Overmyer et al found no significant alterations.  Going forward, incorporation of 
Overeyer et als’ mammalian tissue collection strategy should be considered, especially when targeting 
molecular pathways found to have been altered by drug metabolism.   
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 Lowered resolution of the glucose tolerance test  
Due to ethical concerns, the GTT administered to our guinea pig cohort consisted of limited time points. 
Increased frequency of blood sugar readings was not possible due to the low circulating blood volume in 
the young guinea pigs (6.7ml/100g body weight)159. This resulted in lowered resolution of the glucose 
response curve, preventing in-depth analysis of the subject’s metabolic function (for example 
determination of glucose response phases). We were unable to find significant differences in the limited 
curve characteristics we were able to explore (peak BSL, Δ-peak BSL and AUC), however this may be a 
reflection of the tests lowered resolution rather than a similarity of metabolic response between terms and 
preterms. 
Furthermore, development of a guinea pig insulin assay is currently underway by our colleague, Professor 
David Kennaway at the University of Adelaide. The ability to determine levels of circulating insulin in the 
guinea pig will provide a clearer demonstration of potential metabolism deviations in our preterm cohort, 
however validation of this assay was not completed during the timeframe of the current project.  
 Histological techniques  
 Cryosections and the development of ice artefact 
As lipid are removed by the alcohol and xylol used in tissue paraffin processing, oil red o staining and 
analysis must be performed on frozen, cryosectioned tissue. This technique is associated with increased 
artefact deposition which may potentially impact on diagnosis. A technique championed by Tracy et al in 
2002 gives an alternative to frozen tissue processing by describing a paraffin sectioning technique which 
ensures lipid fixation in formalin fixed tissue 160. The technique uses a process which enriches the tissue 
with additional lipids specifically binding to the naturally deposited lipids within the sample. Exposure to 
chromic acid then fixes the lipids and allows for the introduction of fat soluble stains.  
The Tracy et al method was attempted for use on formalin fixed tissues collected for our study, however 
an adequate result was not attained (See 7.5 Appendix: Lipid fixation protocol validation, Page 102).  
As the protocol was unable to be validated, frozen samples were used for oil red o analysis. To limit ice 
artefact development, tissue was snap frozen in liquid nitrogen and care was taken to avoid unnecessary 
temperature fluctuations when processing the tissue. The resulting slides appeared relatively free from ice 
artefact as tissue architecture appeared undisrupted.  
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 Application of NAS to pre-NAFLD liver tissue  
As our study was interested in the precursor state of NAFLD development, liver physiology was observed 
at a relatively young age. As a result, the characteristics associated with NAFLD (steatosis, inflammation 
and fibrosis) were minimal. The NAS was designed to stage progression of NAFLD, rather than determine a 
predisposition, and therefore, the scoring system is weighted to differentiate cases of greater severity than 
observed in our samples. To increase the detection of inflammation, the magnification at which hepatic 
H&E stained tissue was analysed was altered from Kleiner et als’ recommended x200 magnification to x100 
magnification (used in Liang’s rodent NAS validation) 44,95. In doing so, a greater area of tissue was viewed, 
increasing the likelihood of observing inflammation foci. As the number of foci observed remained minimal 
even with decreased magnification, the average numbers of foci observed were statistically analysed rather 
than the inflammatory NAS score. This allowed differentiation between the majority of samples, which 
would have scored a ’1’ in NAFLD activity. For future studies interested in liver physiology associated with 
NAFLD predisposition, validation of a NAS with increased sensitivity, through assessing the average number 
of foci over a greater sample area, would be a worthwhile endeavour.  
 Zonation of steatosis  
Metabolic zonation within the liver has previously been described due to differential metabolic capabilities 
of hepatocytes relative to periportal proximity 161,162. This pattern is suspected in hepatic triglyceride 
accumulation 163. We therefore employed a method of sampling full face tissue sections through the lobe, 
providing a greater region of tissue to analyse than a biopsy would provide. By averaging steatosis and 
inflammation quantification across multiple sites of the sample, the possible effect of zonation is 
minimised. In order to maintain consistency, the lower right lobe of all subjects was assessed for steatosis. 
Future studies may look to assess steatosis in multiple lobes to ensure steatosis throughout the entire liver 
is reflected and enable greater accuracy of findings.  
 Differential NAFLD presentation in paediatric cases  
Paediatric NAFLD presentation has been shown to differ from adult presentation 96,164. Suspecting NAFLD 
presented differently in paediatric and adult cases, Schwimmer et al set out to categorise manifestations 
of NAFLD in paediatric patients 96. They were able to class NASH presentation into 2 subtypes; Type 1 - 
steatosis with hepatocellular ballooning (typical of adult cases), and Type 2 - steatosis with portal 
inflammation/fibrosis without hepatocellular ballooning. Differences in the steatosis, inflammation and 
fibrosis of less advanced NAFLD cases were not investigated. As hepatic physiology was assessed at a young 
age in the current study, it could be argued that incorporation of Alkhouri et als 164 Pediatric NAFLD 
Histological Score (PNHS) could more accurately quantify NAFLD manifestation in our study. The PNHS 
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recognises the importance of portal inflammation in severe cases of paediatric NASH. As NAFLD 
manifestation was not expected to be severe in our cohort, a NAS which incorporated rodent validation 
and with greater sensitivity was prioritised over use of the PNHS. Images from the current study have been 
retained and will be re-analysed using the PNHS to assess whether this is a more valid approach in the 
current context.  
4.4 Potential future research  
Characterising liver dysfunction and potential predisposition to NAFLD in our guinea pig model of 
prematurity provides a vehicle for studies where human trials are not possible. Results and potential 
interventions highlighted by the current study may then be translated into a clinical setting. In order to 
elucidate the mechanisms underpinning the ex-preterms’ predisposition to liver dysfunction and NAFLD 
development, it will be important to determine correlations between the metabolites we found to be 
altered in preterms, with genes and NALFD pathway function through targeted RNA-seq and principal 
component analysis (PCA). In the present study we have investigated early development of NAFLD 
precursors in the ex-preterm. Future studies will need to investigate if the markers of NAFLD predisposition 
found in our study results in increased NALFD severity later in life, or earlier presentation in ex-preterms 
relative to terms. In testing a cohort of guinea pigs treated in the same manner as this study but with an 
end point relative to human young adulthood (6 months CPNA in our cohort), we would be able to 
determine if the steatosis developed in our ‘young adult’ cohort increases, ameliorates or is stable with 
time. Such an approach would also allow for the testing of novel therapeutics in this vulnerable population. 
In this study, many of the amino acids found to be depleted in the preterm phenotype have previously been 
described as altering liver function in rats. Correcting this deficit via maternal or postnatal supplementation 
regimes represents one such therapeutic strategy. Research into the effects and viability of 
supplementation of these amino acids maybe worthwhile as they may prove useful as interventional 
treatment in cases of preterm predisposition to metabolic dysfunction.   
In humans it is clear that development of disease is multifactorial. The “two-hit” hypothesis states that the 
ex-preterm child/adult is vulnerable to a second insult such as a sedentary lifestyle or western diet. High 
fructose intake, common in the western diet has been proposed as a contributing factor to NAFLD 
development 118,119. Without intervention, preterm children are likely to be exposed to this diet which may 
act as a second ‘hit’, exacerbating predisposition to NALFD in preterms. By incorporating high fructose diet 




This study has characterised the early childhood stage of the preterm phenotype by demonstrating preterm 
deviation from their full term counterparts in growth, metabolism, hepatic physiology and molecular 
alterations associated with NAFLD development. Hepatic steatosis and inflammation observed in our 
preterm cohorts were not severe enough for any of our relatively young subjects to be diagnosed with 
NAFLD. However, the significant increase in steatosis we observed in our preterms can be considered a 
precursor marker of potential NAFLD manifestation. 
Our study was able to demonstrate that the developmental environment of prematurity results in 
significant changes to growth and metabolic function in the neonate. The majority of this deficit is reduced 
upon reaching term equivalent age, however, molecular and physiological changes within the liver persist 
into early childhood. By identifying metabolic, molecular and physiological alterations in the preterm 
guinea pig this study has taken the first steps in understanding the pathways involved in preterm 
susceptibility to NAFLD. 
Furthermore, in identifying the preterms’ predisposition to NAFLD; the hepatic manifestation of metabolic 
syndrome, new opportunities are provided which may allow for early detection of metabolic syndrome 
susceptibility. Metabolic syndrome, a broader metabolic complication associated with increased mortality 
is known to affect ex-preterms at a relatively young age, decreasing their quality of life and inflating the 
burden on the healthcare system. By recognising the precursor markers of NAFLD at a young age, early 
intervention can be administered to attenuate the manifestation of NAFLD and metabolic syndrome. 
Further research is required to determine the specific molecular pathways involved in NAFLD predisposition 
and potential future treatment options. Amino acids associated with liver damage that were found to be 
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7 Appendix  
7.1  Biometric measurements  





                                       (C) 
 
 
Figure 31: Twice weekly biometric measurements – (A) Hock-toe: measured from tip of hock to tip of middle toe (excluding claw). 
(B) Hind limb: measured from ‘knee’ to hock. (C) Crown-rump length: measured from crown where top of the ears attach to 
tailbone.   
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7.2 Preliminary data comparing GTT’s of 6 month old terms and 
preterms 
 
Figure 32: Preliminary data comparing GTT results of 6 month old terms and preterms 
 
Figure 32: Preliminary data comparing GTT results of 6 month old terms and preterms. Solid pink bars represent term females 
(n=7), hashed pink bars represent preterm females (n=8), solid blue bars represent term males (n =8), and blue hashed bars 
represent preterm males (n=7). All data analysed using 2-way ANOVA and presented as group means ± SD. * denotes significance 




7.3 Liver dissection and sampling  








Figure 33: Liver dissection and sampling (A) Excised liver, upper right lobe (1) collected as frozen sample for histology. Left lower 
lobe (2) collected as formalin fixed sample for histology. Remainder of liver (excluding gallbladder) was diced and sampled from 
multiple locations (3) and frozen for LC- MS/MS. (B) 5µm cross sections were taken from the widest part of the lobe in both frozen 
and fixed liver samples. (C) 5 fields of view were sampled from each section.  Indicates the general areas sampled (not to scale).  
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7.4 Solutions  
 Phosphate Buffer  
Disodium 23.7g 
Sodium dihydrogen 6.75g 
DH20  2L 
 
 Haematoxylin and Eosin  
90% Ethanol  
99% Ethanol  900ml 
DH20  100ml 
 
80% Ethanol  
99% Ethanol  800ml 
DH20  200ml 
 
70% Ethanol  
99% Ethanol  700ml 
DH20  300ml 
 
Acid Alcohol 
99% Ethanol  1400ml 
Tap Water  600ml 




Eosin yellowish 1B423  20g 
Ethanol  1600ml 
DH20  400ml 
 
Working solution 
Stock solution  400ml 
Ethanol 1200ml 







Haematoxylin  10g 
70% Ethanol  150ml 
  
Solution B 
Aluminium potassium sulphate  200g 
DH20  2000ml 
 
Working solution 
Solution A  150ml 
Solution B 2000ml 
Sodium Iodate 1g 
Filter 
 
 Masson’s Trichrome 
Bouins solution 
Picric acid (saturated)  75ml 
Formaldehyde (37%) 25ml 
Glacial acetic acid 5ml 
 
Weigert’s Iron Haemotoxylin 
Stock solution A 
Hematoxylin  1g 
95% Ethanol 100ml 
 
Stock solution B 
29% Ferric chloride in H20   4ml 
DH20 95ml 
Concentrated HCL  1ml 
 
Working solution  
Weigerts stock  A  100ml 







Biebrich scarlet-acid fuchsin 
1% Biebrich scarlet  90ml 
1% Acid fushcin 10ml 
Glacial acetic acid 1ml 
 
Phosphomolybdic-phosphotungstic acid 
5% phosphomolybdic- 25ml 
5% phosphotungstic 25ml 
 
Aniline Blue 
Aniline Blue  2.5g 
Glacial acetic acid 2ml 
DH20 99ml 
 
1% Acetic acid 
Glacial acetic acid   1ml 
DH20  99ml 
 
Light green 
Light green  1g 




 Oil Red O 
Oil Red O Stock  
Oil Red O   0.5g 




Dextrin  1g 
DH20 100ml 
 
Oil Red O working solution 
Oil red o stock  60ml 
Dextrin sol 40ml 
Stand for 24hours + 
 
 Lipid Fixation 
Lipid soloution 
Ethylene glycol  500ml 
Linoleic acid 5g 
Lecithin 2g 
Stir for 1hour, let sit for 2+ hours 
and draw off lower phase with 
separatory funnel 
 
2% Chromium trioxide 
chromium trioxide  2g 
DH20 100ml 
 
Sodium bicarbonate soloution 





7.5 Lipid fixation protocol validation 
A large part of this project was investigating the suitability of incorporating a lipid fixation step, 
descried by Tracy et al to allow for paraffin embedded section to be taken and stained with oil red o 
160.  
Historically ORO staining is applied to frozen tissue processed using a cryostat. This technique is 
associated with increased artefact deposition which may potentially impact on diagnosis, but was 
necessary due to fat dissolution by the alcohols used in paraffin processing of fixed tissue. A technique 
championed by Tracy et al in 2002 gives an alternative to frozen tissue processing by describing a 
paraffin sectioning technique which ensures lipid fixation in formalin fixed tissue. The technique uses 
a process which enriches the tissue with additional lipids specifically binding to the naturally deposited 
lipids within the sample. Exposure to chromic acid then fixes the lipids and allows for the introduction 
of fat soluble stains. This provides advantages and opportunities not afforded by frozen sectioning, 
such as the ability to cut sequential sections of tissue for specialty staining, allowing a myriad of tissue 
characteristics to be viewed in the same region of cells.  
Liver tissue and tissues known to include lipids (skin + subcutaneous fat, visceral fat, kidney + visceral 
fat) were collected. All tissue samples were bisected with half fixed in formalin to be given lipid fixation 
treatment and the other half frozen for cryosectioning. Each would be stained using the same oil red 
o and H&E staining procedures and the quality of the stains compared in order to validate the lipid 
fixation protocol (Table 15).  
Table 15: Lipid fixation protocol 
Reagent Duration Temperature Process 
Lipid solution 3 days  56C Impregnate tissue with lipids 
Rinse in 70% ethanol 8 hours  Room temp Remove excess lipid 
Rinse in H20 8 hours  Room temp Remove ethanol 
2% chromic acid  1 day  4C Lipid fixation 
Rinse in H20 1 day Room temp Remove chromic acid 
5% sodium bicarbonate 1 day Room temp Restoration of nuclear staining 





 Lipid fixation attempt #1  
Tissues were embedded in paraffin immediately after completion of lipid fixation. Embedded tissues 
were left overnight. The next morning all tissues had dried out resulting in shrunken and distorted 
tissue (Figure 34a). After re-embedding, tissue was cut and stained. Many of the sections cut had 
trouble remaining on the slide prior to and throughout the staining process (Figure 34b). Liver was the 
only tissue to remain on the slides but tissue damage was prevalent and staining appeared uneven 
and ill-defined, and cells appeared crowded (Figure 34).  
 Lipid fixation attempt #2  
Immediately following lipid fixation tissues were processed overnight according to Table 2 (Page 27), 
embedded and sections cut. Architecture of the tissue was intact and staining was even, however 
lipids had been removed from the tissue during processing (Figure 35).  
 Lipid fixation attempt #3  
In place of processing, the tissues were left to air-dry after lipid fixation. Tissues were placed between 
two biopsy pads within cassettes to prevent distortion (Figure 36). Once dry (after 4 days) tissue was 
placed within a wax bath for 3 hours at 60C, embedded and cut.  
Tissue, especially fat, was under processed and dissolved when placed on waterbath. Kidney and liver 
tissue successfully collected on slides was very damaged with uneven staining (Figure 37).   
 Conclusions drawn from failed attempts  
Attempts at validating the lipid fixation protocol were halted after multiple attempts were made using 
the 3 alterations to the protocol outlined above. It appears processing is necessary after completion 
of the lipid fixation protocol as tissue consistency is not suitable for sectioning due to inadequate 
dehydration and paraffin penetration. However, post lipid fixation, the tissues lost all traces of lipid 












Figure 33: Liver dissection and sampling (A) Distorted liver tissue, post lipid fixation and embedding. (B) Sections of liver cut 
from the same tissue after re-embedding. Tissue can be seen lifting away from slide due to lack of processing. (C) The same 
liver sections stained with oil red o and photographed at x100 magnification. Tissue is cracked and cells are crowded.   
105 
 






Figure 35 (A) Subcutaneous fat processed following attempted lipid fixation (attempt #2). No lipids are visible as they have 
been removed during processing. (B) Subcutaneous fat which has been cryo-sectioned without processing. Lipids are visible 




Figure 36: Tissues left to air dry after lipid fixation (attempt #3) 
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7.6 Suppliers list  
Supplier Country Product 
AB Sciex  USA Analyst v1.6 
  Q-Tarp 5500 mass spectrometer 
Azwood New Zealand Pussydoo cat litter 
BD Singapore 10ml EDTA vacutainers®  
  22g x ½" precisionglide™ needle  
BOC gases New Zealand medical air  
  O2 
Cambridge Isotopes USA NSK-B IS mixture 
  Amino acid IS mixture 
CDN Isotopes USA Amino acid IS mixture 
Drägerwerk AG & Co Germany Dräger 8000 incubator  
Feather Saftey Razor co Japan Feather S35 blades 
Fisher & Paykel Healthcare New Zealand Neopuff Infant T-piece resuscitator 
Fuji Film Australia Sonosite ultrasound  
Graphpad Software USA Prism version 7 
Heinger Switserland Hair clippers 
Interlab New Zealand 80ml specimen container 
  Small histosette 
Jina’s Produce New Zealand Vegetables 
Johnson & Johnson New Zealand KY Jelly 
Knittel Glass Germany StarFrost® microscope slides  
Labserv New Zealand 10% neutral buffered formalin  
  Ethanol 
  Polycine® coated slides 
  Xylene 
Leica Biosystems New Zealand Leica RM2235 microtome  
Liberty® England Tape measure 
McCormick™ Scientific USA Paraffin wax 
National Institutes of Health USA Image J  
OfficeMax® New Zealand 50 x 60mm resealable bags 
Olympus New Zealand BX51 Microscope 
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Supplier Country Product 
  DP20 mounted camera 
Pharmaco Ltd New Zealand CareSens 28G lancets  
  CareSens N Glucometer  
  CareSens N Testing strips 
Phenomenex USA Kinetex HILIC 50 x 4.6mm 2.6µ, column 
ProSciTech Australia Surgical instruments 
Protec New Zealand Cotton tips 
Sakura® Finetek USA Tissue-Tek® Cryoconsole 
  Tissue-Tek® cryostat  
  Tissue-Tek® Glas Mounting Media 
  Tissue-Tek® O.C.T. Compound  
  Tissue-Tek® TEC™ embedding centre 
  Tissue-tek® VIP processor  
Sarstedt Germany Microvette 
Sharpes stock feeds  New Zealand Hay 
Shinko Denshi Japan Vibra electronic scale 
Sigma aldrich Australia Ascorbate acid 
StataCorp USA Stata version 15 
Terumo Phillapines  36g x ½" needle    
10ml luer-loc™ syringe    
32g x 1" needle   
lml luer-lock™ syringe  
Thermo Scientific New Zealand Flotation waterbath   
Menzel-Gläser 22x40 cover slip   
Shandon Immuno-Mount™  
Watties New Zealand Apple babyfood 
Wholesale Landscapes New Zealand Wood shavings 
Wombaroo Food Products Australia Colostrum 




7.7 Drugs list  
Drug Dose Route Manufacturer Country 
Aglepristone 10mg/kg SC Provet New Zealand 
Betamethasone 1mg/kg SC Merck, Sharpe and Dohme New Zealand 
Medetomidine 0.5mg/kg IP Pfizer Animal Health New Zealand 
Ketamine 40mg/kg IP PhoenixPharm Australia 
Oxytocin 3 IU/kg IM Provet New Zealand 
Pentobarbital 300mg/kg IP Provet New Zealand 
 
